mitoxantrone and Acute Myelogenous Leukemia studies

Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.

Research Excerpts

Excerpt	Relevance	Reference
" A phase II trial of flavopiridol followed by ara-C and mitoxantrone with flavopiridol given by 1-h bolus for adults with newly-diagnosed, poor-risk acute myelogenous leukemia yielded 67% complete remission with median disease-free survival of 13."	9.16	Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. ( Carraway, HE; Dorcy, KS; Doyle, LA; Drye, DM; Estey, EH; Garrett-Mayer, E; Gladstone, DE; Gore, SD; Greer, JM; Karp, JE; Levis, MJ; Mackey, K; McDevitt, MA; Othus, M; Pagel, JM; Pratz, KW; Rudek, MA; Showel, MM; Smith, BD; Wright, JJ, 2012)
"The aim of the JCCLSG AML 9805 Down study was to evaluate the effect of continuous and high-dose cytarabine combined chemotherapy on the survival outcome of acute myeloid leukemia (AML) with Down syndrome (DS)."	9.15	Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study. ( Higa, T; Horikoshi, Y; Itoh, M; Iwai, A; Kanegane, H; Kogawa, K; Ogawa, A; Okada, M; Saiwakawa, Y; Shimomura, Y; Taga, T; Tsurusawa, M; Ueyama, J; Watanabe, A; Yamanaka, J, 2011)
" In a Phase II study, flavopiridol 50 mg/m(2) was given by 1-h infusion daily x 3 beginning day 1 followed by 2 g/m(2)/72 h ara-C beginning day 6 and 40 mg/m(2) mitoxantrone on day 9 (FLAM) to 45 adults with newly diagnosed acute myelogenous leukemia (AML) with multiple poor-risk features."	9.14	Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. ( Alino, K; Blackford, A; Bolaños-Meade, J; Carraway, HE; Doyle, LA; Gore, SD; Greer, JM; Jones, RJ; Karp, JE; Levis, MJ; McDevitt, MA; Seung, AH; Smith, BD; Wright, JJ, 2010)
" In a phase I study of flavopiridol followed by 1-beta-d-arabinofuranosylcytosine (ara-C) and mitoxantrone, overall response rate for adults with relapsed and refractory acute myelogenous leukemias (AML) was 31%."	9.12	Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. ( Briel, J; Colevas, AD; Gore, SD; Greer, J; Hattenburg, C; Jones, RJ; Karp, JE; Levis, MJ; Smith, BD; Wright, JJ, 2007)
" In a chemoimmunotherapy trial conducted between 1997 and 2003 in patients with stage IV indolent lymphoma, 202 patients were treated and 8 have developed MDS between 1 and 5 years after therapy, including 4 who received only fludarabine, mitoxantrone, and dexamethasone (FND) for 6 to 8 courses, with or without rituximab, followed by interferon alpha (IFN-alpha)."	9.11	Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. ( Ayala, A; Estey, E; Glassman, A; Hagemeister, FB; Hayes, K; Maddox, AM; McLaughlin, P; Preti, HA; Romaguera, J; Samaniego, F, 2005)
"Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML)."	9.10	Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. ( Bernard, M; Berthou, C; Campos, L; de Crémoux, P; Delain, M; Drenou, B; Falkenrodt, A; Fernandes, J; Garnache, F; Guilhot, F; Harousseau, JL; Hunault-Berger, M; Kara-Slimane, F; Lioure, B; Moreau, P; Mounier, C; Mugneret, F; Solary, E; Witz, B, 2003)
"A dose-escalation study was realized in order to assess the maximally tolerated dose (MTD) of high-dose mitoxantrone in a single injection combined with cytarabine and etoposide (EMA regimen) in refractory or relapsed acute myelogenous leukemia (AML)."	9.09	Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia. ( Archimbaud, E; Cambier, N; Ecstein-Fraïssé, E; Leblond, V; Pautas, C; Reman, O; Soler-Michel, P; Taksin, AL; Thomas, X; Vekhoff, A, 2000)
"Remission induction chemotherapy for acute myelogenous leukemia typically combines cytarabine with an anthracycline or anthracycline derivative."	9.09	Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor. ( Andresen, S; Elson, P; Hussein, M; Kalaycio, M; Lichtin, A; Pohlman, B; Tripp, B, 2001)
"Fifty-nine patients who received mitoxantrone as part of adjuvant chemotherapy for breast cancer between 1986 and 1992 were studied to determine the incidence of t-AML and t-MDS."	9.08	Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin. ( Cremin, P; Daly, PA; Flattery, M; McCann, SR, 1996)
"In an effort to determine if cell cycle active agents are augmented when given after non-cell cycle active agents, 104 patients with either multiply relapsed or refractory acute nonlymphocytic leukemia or blast crisis of chronic myelogenous leukemia were treated with mitoxantrone."	9.07	Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study. ( Bennett, J; Browman, G; Bryant, J; Goldberg, J; Grunwald, H; Gryn, J; Larson, R; Preisler, H; Raza, A; Vogler, R, 1993)
"Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), given intravenously 5 micrograms/kg per day, was administered on days 4-8 of timed-sequential chemotherapy (TSC) with mitoxantrone, 12 mg/m2 per day on days 1-3, etoposide, 200 mg/m2 per day on days 8-10 and cytarabine, 500 mg/m2 per day on days 1-3 and 8-10, in 22 patients aged < 60 years with refractory acute myelogenous leukemia in an attempt to increase recruitment of leukemic cells in S phase before the second sequence of TSC."	9.07	Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. ( Archimbaud, E; Auzanneau, G; Cordonnier, C; Fenaux, P; Leblond, V; Marie, JP; Reiffers, J; Tilly, H; Travade, P; Troussard, X, 1993)
"A total of 47 patients with relapsed or primarily refractory leukemia were treated with mitoxantrone alone or in combination with vincristine sulfate and prednisone or cytarabine."	9.05	Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. ( Cuttner, J; Holland, JF; Paciucci, PA, 1984)
"The review assessed the efficacy and tolerability of mitoxantrone in patients with neuromyelitis optica spectrum disorder (NMOSD)."	9.01	Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. ( Enriquez, CAG; Espiritu, AI; Pasco, PMD, 2019)
"To evaluate the incidence and dose-dependency of mitoxantrone (MTX)-associated acute myelocytic leukemia (AML) in the network of Italian multiple sclerosis (MS) clinics."	7.77	Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. ( Amato, MP; Bellantonio, P; Bergamaschi, R; Capobianco, M; Capra, R; Cocco, E; Comi, G; Gallo, P; Gasperini, C; Ghezzi, A; Grimaldi, LM; Lugaresi, A; Mancardi, GL; Martinelli, V; Pesci, I; Ponzio, M; Pozzilli, C; Rodegher, M; Salemi, G; Straffi, L; Trojano, M, 2011)
"The objective in this paper is to compare the cumulative incidence and incidence density of therapy-related acute myeloid leukaemia in two cohorts of patients with multiple sclerosis treated with mitoxantrone, and with previously reported data in the literature."	7.75	Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. ( Abellán, I; Belenguer, A; Boscá, I; Casanova, B; Coret, F; Fernández, P; Magraner, MJ; Mallada, J; Montalbán, X; Pascual, AM; Sanz, MA; Sempere, AP; Téllez, N, 2009)
"Acute myeloid leukemia (t-AML) is one of the worst adverse events of mitoxantrone treatment, but the exact risk in multiple sclerosis (MS) patients is not yet known."	7.74	Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis. ( Avonto, L; Bertolotto, A; Cambrin, GR; Capobianco, M; Fava, C; Malucchi, S; Saglio, G; Ulisciani, S, 2008)
"A 58-year-old male with migraine headaches, complex partial epilepsy, and secondary progressive multiple sclerosis treated with mitoxantrone was admitted to our facility in August 2005 with febrile neutropenia, worsening ataxia, aphasia, cough, and declining mental status."	7.74	Therapy-related acute nonlymphoblastic leukemia following mitoxantrone therapy in a patient with multiple sclerosis. ( Dreiling, B; Sumrall, A, 2007)
" We report here on the unusual case of a patient with acute myelogenous leukemia and zygomycosis unresponsive to monotherapy with liposomal amphotericin B, who responded favorably following the addition of the echinocandin caspofungin acetate."	7.73	Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B. ( Caballero, D; Mateos, JJ; Perez, E; San Miguel, JF; Sanz-Rodriguez, C; Vazquez, L, 2005)
" We observed 10 cases of such t-AML over a 7-year-period in breast cancer patients treated with mitoxantrone combined with fluorouracil, cyclophosphamide and regional radiotherapy, and in three cases with vindesine."	7.70	Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. ( Barin, C; Benboubker, L; Binet, C; Brémond, JL; Calais, G; Cartron, G; Colombat, P; Delain, M; Georget, MT; Lamagnère, JP; Leloup, R; Letortorec, S; Linassier, C; Petit, A; Raban, N, 2000)
"Twenty-seven patients with acute myelogenous leukemia (AML) were given remission induction treatment with mitoxantrone, etoposide and cytosine arabinoside (ara-C)."	7.69	Pharmacokinetics of mitoxantrone, etoposide and cytosine arabinoside in leukemic cells during treatment of acute myelogenous leukemia--relationship to treatment outcome and bone marrow toxicity. ( Björkholm, M; Gruber, A; Liliemark, E; Liliemark, J; Paul, C; Peterson, C; Tidefelt, U, 1995)
"The objective of this study was to determine the response rate and toxicity of high-dose cytosine arabinoside (AC) and mitoxantrone (M) in relapsed or refractory childhood acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) and to correlate response with the expression of the multidrug resistance gene 1 (mdr1)."	7.69	Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relationship to multidrug resistance gene 1. ( Cairo, MS; Feusner, J; Gold, SH; Knoppell, E; Krill, CE; Moulton, TA; Odom, LF; Waldron, P; Wells, RJ; White, ML, 1994)
"We have previously documented that adults with de novo acute myelogenous leukemia (AML) who are induced into first complete remission with mitoxantrone and high-dose cytarabine are more likely than those induced with daunorubicin and high-dose cytarabine to develop a bone marrow injury pattern with delayed cytopenias after achieving initial complete remission, a phenomenon we have termed post-remission cytopenia syndrome."	7.69	Delayed engraftment of 4-hydroperoxycyclophosphamide-purged autologous bone marrow after induction treatment containing mitoxantrone for acute myelogenous leukemia. ( Damon, LE; Linker, CA; Ries, CA; Rugo, HS, 1996)
"Intensive sequential chemotherapy with mitoxantrone, 12 mg/m2/d on days 1 through 3, etoposide, 200 mg/m2/d as a continuous infusion on days 8 through 10, and cytarabine, 500 mg/m2/d as a continuous infusion on days 1 through 3 and 8 through 10 was administered to 72 patients aged less than 60 years with previously treated acute myelogenous leukemia (AML)."	7.68	Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. ( Archimbaud, E; Cordonnier, C; Devaux, Y; Dreyfus, F; Fenaux, P; Fiere, D; Jaubert, J; Leblond, V; Michallet, M; Travade, P, 1991)
"Therapy-related acute non-lymphocytic leukemia or preleukemia was observed in five of 71 patients with advanced breast cancer treated with combination chemotherapy comprising prednimustine, methotrexate, 5-fluorouracil, mitoxantrone, and tamoxifen."	7.68	High risk of therapy-related leukemia and preleukemia after therapy with prednimustine, methotrexate, 5-fluorouracil, mitoxantrone, and tamoxifen for advanced breast cancer. ( Andersson, M; Pedersen-Bjergaard, J; Philip, P, 1990)
"23 adult patients with refractory or relapsed acute myelogenous leukemia (AML) received salvage chemotherapy with mitoxantrone and etoposide."	7.67	Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia. ( Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Inverardi, D; Lazzarino, M; Merante, S; Morra, E; Orlandi, E; Pagnucco, G, 1989)
"Forty-four patients with a diagnosis of refractory or relapsed acute myelogenous leukemia received salvage chemotherapy with high-dose cytosine arabinosine 3 g/m2 intravenously over 2 hours every 12 hours for six doses and mitoxantrone 5 mg/m2 intravenously daily for 5 days."	7.67	Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. ( Andersson, B; Beran, M; Estey, EH; Freireich, EJ; Kantarjian, HM; Keating, MJ; McCredie, KB; Plunkett, WK; Walters, RS, 1988)
"Both mitoxantrone and etoposide have been shown to be active in monotherapy trials of relapsed and refractory acute myelogenous leukemia (AML)."	7.67	Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen. ( Ehninger, G; Freund, M; Ho, AD; Hunstein, W; Illiger, HJ; Lipp, T; Meyer, P, 1988)
"We have investigated the efficacy of mitoxantrone in combination with etoposide in patients with refractory acute myelogenous leukemia."	7.67	Combination therapy with mitoxantrone and etoposide in refractory acute myelogenous leukemia. ( Ehninger, G; Freund, M; Ho, AD; Hunstein, W; Lipp, T; Meyer, P, 1986)
"Mitoxantrone is an intravenous anthracenedione structurally related to the anthracycline antibiotics."	6.40	Mitoxantrone in the treatment of acute myelogenous leukemia: a review. ( Archimbaud, E; Thomas, X, 1997)
"A disseminated Fusarium infection due to F."	5.39	Refractory disseminated fusariosis by Fusarium verticillioides in a patient with acute myeloid leukaemia relapsed after allogeneic hematopoietic stem cell transplantation: a case report and literature review. ( Bartolesi, AM; Fanci, R; Pecile, P; Pini, G, 2013)
"Mitoxantrone is a synthetic aminoanthraquinone we have previously reported to be effective for patients with acute leukemia in relapse."	5.27	Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia. ( Cuttner, J; Dutcher, JP; Holland, JF; Paciucci, PA; Strauman, JJ; Wiernik, PH, 1987)
"Fludarabine is an effective treatment for follicular lymphoma (FL), but exposure to it negatively impacts stem cell mobilization and may increase the risk of subsequent myelodysplastic syndrome and acute myelogenous leukemia (t-MDS/AML)."	5.16	Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. ( Andresen, S; Bolwell, B; Copelan, E; Dean, R; Kalaycio, M; Pohlman, B; Rybicki, L; Sobecks, R; Sweetenham, J; Waterman, J, 2012)
" The mTOR signaling pathway is frequently activated in acute myelogenous leukemia (AML) and we previously showed the safety of combining the mTOR inhibitor, sirolimus, with mitoxantrone, etoposide, and cytarabine (MEC) chemotherapy."	5.16	Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. ( Carroll, M; Kasner, MT; Luger, SM; Perl, AE; Shank, D, 2012)
" A phase II trial of flavopiridol followed by ara-C and mitoxantrone with flavopiridol given by 1-h bolus for adults with newly-diagnosed, poor-risk acute myelogenous leukemia yielded 67% complete remission with median disease-free survival of 13."	5.16	Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. ( Carraway, HE; Dorcy, KS; Doyle, LA; Drye, DM; Estey, EH; Garrett-Mayer, E; Gladstone, DE; Gore, SD; Greer, JM; Karp, JE; Levis, MJ; Mackey, K; McDevitt, MA; Othus, M; Pagel, JM; Pratz, KW; Rudek, MA; Showel, MM; Smith, BD; Wright, JJ, 2012)
"The aim of the JCCLSG AML 9805 Down study was to evaluate the effect of continuous and high-dose cytarabine combined chemotherapy on the survival outcome of acute myeloid leukemia (AML) with Down syndrome (DS)."	5.15	Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study. ( Higa, T; Horikoshi, Y; Itoh, M; Iwai, A; Kanegane, H; Kogawa, K; Ogawa, A; Okada, M; Saiwakawa, Y; Shimomura, Y; Taga, T; Tsurusawa, M; Ueyama, J; Watanabe, A; Yamanaka, J, 2011)
" In a Phase II study, flavopiridol 50 mg/m(2) was given by 1-h infusion daily x 3 beginning day 1 followed by 2 g/m(2)/72 h ara-C beginning day 6 and 40 mg/m(2) mitoxantrone on day 9 (FLAM) to 45 adults with newly diagnosed acute myelogenous leukemia (AML) with multiple poor-risk features."	5.14	Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. ( Alino, K; Blackford, A; Bolaños-Meade, J; Carraway, HE; Doyle, LA; Gore, SD; Greer, JM; Jones, RJ; Karp, JE; Levis, MJ; McDevitt, MA; Seung, AH; Smith, BD; Wright, JJ, 2010)
"In January 2007, SWOG 9921 was closed to further accrual after three cases of acute myelogenous leukemia (AML) were reported of a total of 487 patients in the mitoxantrone treatment arm."	5.13	Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. ( Crawford, ED; Flaig, TW; Glodé, LM; Hussain, MH; Raghavan, D; Stadler, WM; Tangen, CM, 2008)
" In a phase I study of flavopiridol followed by 1-beta-d-arabinofuranosylcytosine (ara-C) and mitoxantrone, overall response rate for adults with relapsed and refractory acute myelogenous leukemias (AML) was 31%."	5.12	Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. ( Briel, J; Colevas, AD; Gore, SD; Greer, J; Hattenburg, C; Jones, RJ; Karp, JE; Levis, MJ; Smith, BD; Wright, JJ, 2007)
" In a chemoimmunotherapy trial conducted between 1997 and 2003 in patients with stage IV indolent lymphoma, 202 patients were treated and 8 have developed MDS between 1 and 5 years after therapy, including 4 who received only fludarabine, mitoxantrone, and dexamethasone (FND) for 6 to 8 courses, with or without rituximab, followed by interferon alpha (IFN-alpha)."	5.11	Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. ( Ayala, A; Estey, E; Glassman, A; Hagemeister, FB; Hayes, K; Maddox, AM; McLaughlin, P; Preti, HA; Romaguera, J; Samaniego, F, 2005)
"Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML)."	5.10	Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. ( Bernard, M; Berthou, C; Campos, L; de Crémoux, P; Delain, M; Drenou, B; Falkenrodt, A; Fernandes, J; Garnache, F; Guilhot, F; Harousseau, JL; Hunault-Berger, M; Kara-Slimane, F; Lioure, B; Moreau, P; Mounier, C; Mugneret, F; Solary, E; Witz, B, 2003)
"Cytarabine is an essential drug for inducing remission of acute myelogenous leukemia, and it is also one the most effective drugs used as salvage therapy for patients with all types of relapsed acute leukemia."	5.09	A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia. ( Estey, E; Feldman, EJ; Kantarjian, HM; Keating, M; Koller, CA; O'Brien, S; Rios, MB, 1999)
"A dose-escalation study was realized in order to assess the maximally tolerated dose (MTD) of high-dose mitoxantrone in a single injection combined with cytarabine and etoposide (EMA regimen) in refractory or relapsed acute myelogenous leukemia (AML)."	5.09	Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia. ( Archimbaud, E; Cambier, N; Ecstein-Fraïssé, E; Leblond, V; Pautas, C; Reman, O; Soler-Michel, P; Taksin, AL; Thomas, X; Vekhoff, A, 2000)
"Remission induction chemotherapy for acute myelogenous leukemia typically combines cytarabine with an anthracycline or anthracycline derivative."	5.09	Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor. ( Andresen, S; Elson, P; Hussein, M; Kalaycio, M; Lichtin, A; Pohlman, B; Tripp, B, 2001)
"To improve outcome in high-risk patients, high-dose cytarabine and mitoxantrone (HAM) was introduced into the treatment of children with acute myelogenous leukemia (AML) in study AML-BFM 93."	5.09	Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93. ( Berthold, F; Creutzig, U; Gadner, H; Havers, W; Henze, G; Hermann, J; Jürgens, H; Kabisch, H; Kluba, U; Niggli, F; Reinhardt, D; Reiter, A; Ritter, J; Zimmermann, M, 2001)
"Fifty-nine patients who received mitoxantrone as part of adjuvant chemotherapy for breast cancer between 1986 and 1992 were studied to determine the incidence of t-AML and t-MDS."	5.08	Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin. ( Cremin, P; Daly, PA; Flattery, M; McCann, SR, 1996)
"In an effort to determine if cell cycle active agents are augmented when given after non-cell cycle active agents, 104 patients with either multiply relapsed or refractory acute nonlymphocytic leukemia or blast crisis of chronic myelogenous leukemia were treated with mitoxantrone."	5.07	Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study. ( Bennett, J; Browman, G; Bryant, J; Goldberg, J; Grunwald, H; Gryn, J; Larson, R; Preisler, H; Raza, A; Vogler, R, 1993)
"In a phase I study, 68 patients with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and accelerated- and blastic-phase CML received induction therapy consisting of cytarabine 3 g/m2 by infusion over 3 hours daily for 5 days, with escalating doses of mitoxantrone 40 to 80 mg/m2 over 1 to 2 days by intravenous infusion over 15 minutes."	5.07	Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. ( Ahmed, T; Alberts, DS; Arlin, Z; Baier, M; Baskind, P; Feldman, EJ; Mittelman, A; Peng, YM; Plezia, P, 1993)
"Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), given intravenously 5 micrograms/kg per day, was administered on days 4-8 of timed-sequential chemotherapy (TSC) with mitoxantrone, 12 mg/m2 per day on days 1-3, etoposide, 200 mg/m2 per day on days 8-10 and cytarabine, 500 mg/m2 per day on days 1-3 and 8-10, in 22 patients aged < 60 years with refractory acute myelogenous leukemia in an attempt to increase recruitment of leukemic cells in S phase before the second sequence of TSC."	5.07	Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. ( Archimbaud, E; Auzanneau, G; Cordonnier, C; Fenaux, P; Leblond, V; Marie, JP; Reiffers, J; Tilly, H; Travade, P; Troussard, X, 1993)
"A total of 47 patients with relapsed or primarily refractory leukemia were treated with mitoxantrone alone or in combination with vincristine sulfate and prednisone or cytarabine."	5.05	Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. ( Cuttner, J; Holland, JF; Paciucci, PA, 1984)
"The review assessed the efficacy and tolerability of mitoxantrone in patients with neuromyelitis optica spectrum disorder (NMOSD)."	5.01	Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. ( Enriquez, CAG; Espiritu, AI; Pasco, PMD, 2019)
"A 64-year-old man with acute myelogenous leukemia (FAB classification, M7) in remission received consolidation chemotherapy with mitoxantrone/cytosine arabinoside."	4.85	[Bacillus cereus sepsis and subarachnoid hemorrhage following consolidation chemotherapy for acute myelogenous leukemia]. ( Gondo, H; Kawatani, E; Kishikawa, Y; Kuwahara, N; Matsuishi, E; Mori, D; Osoegawa, K; Sankoda, C, 2009)
"High-dose mitoxantrone therapy is associated with an excellent remission rate but with a significantly increased risk of clinical and subclinical early cardiotoxicity and heart failure."	3.83	Mitoxantrone-Induced Cardiotoxicity in Acute Myeloid Leukemia-A Velocity Vector Imaging Analysis. ( Ahmed, M; Aurigemma, GP; Cerny, J; Escobar, J; Kane, JL; McGuiness, ME; McManus, DD; Meyer, TE; Nath, R; Ramanathan, M; Shaikh, AY; Shih, J; Suryadevara, S; Tighe, DA; Tripathi, A, 2016)
"Mitoxantrone (MTZ) has been shown to be effective in the treatment of newly diagnosed acute myeloblastic leukemia (AML)."	3.81	A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia. ( Canpinar, H; Kansu, E; Kars, A; Koc, Y; Oyan, B; Tekuzman, G, 2004)
"The gene for Werner's syndrome (WRN) encodes a recQ helicase."	3.81	Severe toxicity following induction chemotherapy for acute myelogenous leukemia in a patient with Werner's syndrome. ( Agoliati, G; Ahmed, T; Arshad, M; Galvin-Parton, P; Liu, D; Qureshi, A; Seiter, K, 2005)
"The efficacy of fludarabine in combination with an intermediate dose of cytosine arabinoside, mitoxantrone, and G-CSF (FLANG; fludarabine 30 mg/m(2)/day, cytosine arabinoside 1 g/m(2)/day, mitoxantrone 10 mg/m(2)/day, and G-CSF 300 μg/day for 5 days) was evaluated in patients with refractory or relapsed acute myelogenous leukemia (AML)."	3.77	FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia. ( Cho, BS; Cho, SG; Choi, SM; Eom, KS; Kim, CC; Kim, HJ; Kim, YJ; Lee, DG; Lee, JW; Lee, S; Min, CK; Min, WS, 2011)
"To evaluate the incidence and dose-dependency of mitoxantrone (MTX)-associated acute myelocytic leukemia (AML) in the network of Italian multiple sclerosis (MS) clinics."	3.77	Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. ( Amato, MP; Bellantonio, P; Bergamaschi, R; Capobianco, M; Capra, R; Cocco, E; Comi, G; Gallo, P; Gasperini, C; Ghezzi, A; Grimaldi, LM; Lugaresi, A; Mancardi, GL; Martinelli, V; Pesci, I; Ponzio, M; Pozzilli, C; Rodegher, M; Salemi, G; Straffi, L; Trojano, M, 2011)
" We characterized, at the genomic level, the t(16;21) translocation in a patient who developed t-AML after treatment of multiple sclerosis with mitoxantrone (MTZ)."	3.75	Identification of a potential "hotspot" DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation. ( Amadori, S; Ammatuna, E; Bovetti, K; Chessa, L; Conte, E; Curzi, P; Divona, M; Ferrari, A; Grimwade, D; Hasan, SK; Lavorgna, S; Lo-Coco, F; Mays, AN; Montefusco, E; Noguera, NI; Ottone, T, 2009)
"Therapy-related acute leukaemia (TRAL) is a concern for neurologists and patients when considering treatment with Mitoxantrone for multiple sclerosis (MS)."	3.75	Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it? ( Boggild, M; Ellis, R, 2009)
"The objective in this paper is to compare the cumulative incidence and incidence density of therapy-related acute myeloid leukaemia in two cohorts of patients with multiple sclerosis treated with mitoxantrone, and with previously reported data in the literature."	3.75	Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. ( Abellán, I; Belenguer, A; Boscá, I; Casanova, B; Coret, F; Fernández, P; Magraner, MJ; Mallada, J; Montalbán, X; Pascual, AM; Sanz, MA; Sempere, AP; Téllez, N, 2009)
"Acute myeloid leukemia (t-AML) is one of the worst adverse events of mitoxantrone treatment, but the exact risk in multiple sclerosis (MS) patients is not yet known."	3.74	Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis. ( Avonto, L; Bertolotto, A; Cambrin, GR; Capobianco, M; Fava, C; Malucchi, S; Saglio, G; Ulisciani, S, 2008)
"We report two new cases of mitoxantrone-related leukemia occurring in two patients with multiple sclerosis (MS), 14 and 18 months after the last infusion of the drug."	3.74	Mitoxantrone-related acute leukemia in two MS patients. ( Gille, M; Goffette, S; Pielen, A; Sindic, CJ; Van Pesch, V, 2008)
"A 58-year-old male with migraine headaches, complex partial epilepsy, and secondary progressive multiple sclerosis treated with mitoxantrone was admitted to our facility in August 2005 with febrile neutropenia, worsening ataxia, aphasia, cough, and declining mental status."	3.74	Therapy-related acute nonlymphoblastic leukemia following mitoxantrone therapy in a patient with multiple sclerosis. ( Dreiling, B; Sumrall, A, 2007)
" We report here on the unusual case of a patient with acute myelogenous leukemia and zygomycosis unresponsive to monotherapy with liposomal amphotericin B, who responded favorably following the addition of the echinocandin caspofungin acetate."	3.73	Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B. ( Caballero, D; Mateos, JJ; Perez, E; San Miguel, JF; Sanz-Rodriguez, C; Vazquez, L, 2005)
" We observed 10 cases of such t-AML over a 7-year-period in breast cancer patients treated with mitoxantrone combined with fluorouracil, cyclophosphamide and regional radiotherapy, and in three cases with vindesine."	3.70	Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. ( Barin, C; Benboubker, L; Binet, C; Brémond, JL; Calais, G; Cartron, G; Colombat, P; Delain, M; Georget, MT; Lamagnère, JP; Leloup, R; Letortorec, S; Linassier, C; Petit, A; Raban, N, 2000)
"Twenty-seven patients with acute myelogenous leukemia (AML) were given remission induction treatment with mitoxantrone, etoposide and cytosine arabinoside (ara-C)."	3.69	Pharmacokinetics of mitoxantrone, etoposide and cytosine arabinoside in leukemic cells during treatment of acute myelogenous leukemia--relationship to treatment outcome and bone marrow toxicity. ( Björkholm, M; Gruber, A; Liliemark, E; Liliemark, J; Paul, C; Peterson, C; Tidefelt, U, 1995)
"The objective of this study was to determine the response rate and toxicity of high-dose cytosine arabinoside (AC) and mitoxantrone (M) in relapsed or refractory childhood acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) and to correlate response with the expression of the multidrug resistance gene 1 (mdr1)."	3.69	Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relationship to multidrug resistance gene 1. ( Cairo, MS; Feusner, J; Gold, SH; Knoppell, E; Krill, CE; Moulton, TA; Odom, LF; Waldron, P; Wells, RJ; White, ML, 1994)
"We have previously documented that adults with de novo acute myelogenous leukemia (AML) who are induced into first complete remission with mitoxantrone and high-dose cytarabine are more likely than those induced with daunorubicin and high-dose cytarabine to develop a bone marrow injury pattern with delayed cytopenias after achieving initial complete remission, a phenomenon we have termed post-remission cytopenia syndrome."	3.69	Delayed engraftment of 4-hydroperoxycyclophosphamide-purged autologous bone marrow after induction treatment containing mitoxantrone for acute myelogenous leukemia. ( Damon, LE; Linker, CA; Ries, CA; Rugo, HS, 1996)
"Among 35 patients with relapsed or refractory acute myelogenous leukemia (AML) who received salvage chemotherapy, 28 were treated with mitoxantrone (7."	3.68	Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia. ( Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, C; McCredie, K; O'Brien, S, 1991)
"Intensive sequential chemotherapy with mitoxantrone, 12 mg/m2/d on days 1 through 3, etoposide, 200 mg/m2/d as a continuous infusion on days 8 through 10, and cytarabine, 500 mg/m2/d as a continuous infusion on days 1 through 3 and 8 through 10 was administered to 72 patients aged less than 60 years with previously treated acute myelogenous leukemia (AML)."	3.68	Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. ( Archimbaud, E; Cordonnier, C; Devaux, Y; Dreyfus, F; Fenaux, P; Fiere, D; Jaubert, J; Leblond, V; Michallet, M; Travade, P, 1991)
"The inhibitory effects of a 1 h exposure to pharmacologically relevant concentrations of the anthracenedione mitoxantrone were assessed with respect to the in vitro clonogenic growth of leukemic myeloblasts obtained from patients with acute myelogenous leukemia (AML)."	3.68	Effect of pharmacologically relevant concentrations of mitoxantrone on the in vitro growth of leukemic blast progenitors. ( Arlin, Z; Feldman, E; Gewirtz, D; Grant, S, 1991)
"Therapy-related acute non-lymphocytic leukemia or preleukemia was observed in five of 71 patients with advanced breast cancer treated with combination chemotherapy comprising prednimustine, methotrexate, 5-fluorouracil, mitoxantrone, and tamoxifen."	3.68	High risk of therapy-related leukemia and preleukemia after therapy with prednimustine, methotrexate, 5-fluorouracil, mitoxantrone, and tamoxifen for advanced breast cancer. ( Andersson, M; Pedersen-Bjergaard, J; Philip, P, 1990)
"23 adult patients with refractory or relapsed acute myelogenous leukemia (AML) received salvage chemotherapy with mitoxantrone and etoposide."	3.67	Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia. ( Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Inverardi, D; Lazzarino, M; Merante, S; Morra, E; Orlandi, E; Pagnucco, G, 1989)
"Forty-four patients with a diagnosis of refractory or relapsed acute myelogenous leukemia received salvage chemotherapy with high-dose cytosine arabinosine 3 g/m2 intravenously over 2 hours every 12 hours for six doses and mitoxantrone 5 mg/m2 intravenously daily for 5 days."	3.67	Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. ( Andersson, B; Beran, M; Estey, EH; Freireich, EJ; Kantarjian, HM; Keating, MJ; McCredie, KB; Plunkett, WK; Walters, RS, 1988)
"Both mitoxantrone and etoposide have been shown to be active in monotherapy trials of relapsed and refractory acute myelogenous leukemia (AML)."	3.67	Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen. ( Ehninger, G; Freund, M; Ho, AD; Hunstein, W; Illiger, HJ; Lipp, T; Meyer, P, 1988)
"We have investigated the efficacy of mitoxantrone in combination with etoposide in patients with refractory acute myelogenous leukemia."	3.67	Combination therapy with mitoxantrone and etoposide in refractory acute myelogenous leukemia. ( Ehninger, G; Freund, M; Ho, AD; Hunstein, W; Lipp, T; Meyer, P, 1986)
"A patient with acute myelogenous leukemia in relapse developed reversible bilateral lateral rectus muscle palsy and cerebellar dysfunction after receiving chemotherapy with high-dose cytosine arabinoside and mitoxantrone."	3.67	Reversible bilateral lateral rectus muscle palsy associated with high-dose cytosine arabinoside and mitoxantrone therapy. ( Castellanos, AM; Glass, JP; Keating, MJ; Ventura, GJ, 1986)
"Cardiotoxicity was ascertained through adverse event monitoring over the course of follow-up among 1,022 pediatric patients with acute myeloid leukemia treated in the Children's Oncology Group trial AAML0531."	2.90	Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group. ( Alonzo, T; Aplenc, R; Gamis, A; Gerbing, RB; Getz, KD; Ky, B; Leahy, AB; Leger, KJ; Sack, L; Sung, L; Woods, WG, 2019)
" A phase I trial of the second-generation proteasome inhibitor ixazomib in combination with MEC (mitoxantrone, etoposide, and cytarabine) was conducted in patients with R/R AML."	2.90	A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia. ( Advani, AS; Caimi, P; Carew, J; Carraway, H; Chan, R; Cooper, B; de Lima, M; Elson, P; Gerds, A; Hamilton, B; Kalaycio, M; Little, J; Maciejewski, J; Malek, E; Miron, A; Mukherjee, S; Nazha, A; Pink, J; Sekeres, MA; Sobecks, R; Tomlinson, B; Unger, A; Visconte, V; Wei, W, 2019)
"Lenalidomide is an immunomodulatory drug that may modulate anti-tumor immunity."	2.87	A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. ( Amrein, PC; Attar, EC; Avigan, D; Ballen, KK; Brunner, AM; DeAngelo, DJ; Ebert, BL; Fathi, AT; Hobbs, GS; Luptakova, K; McMasters, M; Rosenblatt, J; Sperling, AS; Steensma, DP; Stone, RM; Stroopinsky, D; Wadleigh, M; Washington, A; Werner, L, 2018)
"Outcomes for children with acute myeloid leukemia (AML) have improved over the past 20 years even though the medications used for induction therapy have not changed."	2.84	Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials. ( Alexander, TB; Inaba, H; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Triplett, BM; Wang, L, 2017)
"A total of 157 infections occurred in 61 patients (60."	2.82	Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004. ( Bochennek, K; Creutzig, U; Gilfert, J; Hassler, A; Lehrnbecher, T; Perner, C; Reinhardt, D; Schöning, S, 2016)
"Patients with acute myeloid leukemia (AML) in first relapse after initial Complete Remission (CR) lasting ≥1 month were stratified per the European Prognostic Index (EPI) into favorable, intermediate, and poor-risk groups based on duration of first CR, cytogenetics, age, and transplant history."	2.80	Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. ( Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K, 2015)
"Maintenance treatment also reduced minimal residual disease (detected by WT1 and CBFβ-MYH11) in five of eight evaluable patients."	2.79	Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents. ( Audisio, E; Boccadoro, M; Bruno, B; Crisà, E; Ferrero, D; Festuccia, M; Frairia, C; Gatti, T; Giai, V; Marmont, F; Passera, R; Riera, L, 2014)
"The interaction of acute myeloid leukemia (AML) blasts with the leukemic microenvironment is postulated to be an important mediator of resistance to chemotherapy and disease relapse."	2.77	A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. ( Abboud, CN; Cashen, AF; DiPersio, JF; Hladnik, LM; Kulkarni, S; McFarland, K; Motabi, IH; Rettig, MP; Stockerl-Goldstein, KE; Trinkaus, KM; Uy, GL; Vij, R; Westervelt, P, 2012)
"The most effective regimen for relapsed acute myeloid leukemia (AML) patients who do not achieve complete remission (CR) after a course of salvage therapy has not been established."	2.77	Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy. ( Agha, M; Boyiadzis, M; Duggal, S; Hou, JZ; Im, A; Lin, Y; McLaughlin, B; Raptis, A; Redner, R; Smith, C, 2012)
" This decrease suggests that daunorubicin, cytosine arabinoside, etoposide and mitoxantrone may impair the metabolism of other active substances metabolized by this isoenzyme, which should be taken into consideration in planning the dosage scheme in individual patients and considering interactions between drugs."	2.76	Influence of anticancer therapy on oxidation phenotype and acetylation phenotype in patients with acute myeloblastic leukemia. ( Czarnik-Matusewicz, H; Ganczarski, G; Gąsiorowski, J; Głowacka, K; Kuliczkowski, K; Orzechowska-Juzwenko, K; Wiela-Hojeńska, A; Wołowiec, D; Łapiński, Ł, 2011)
"Three of 11 patients with acute lymphoblastic leukemia (ALL) had complete responses while no patient with acute myeloid leukemia (AML) had an objective response."	2.75	Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group. ( Arceci, RJ; Bernstein, M; Buck, S; Chang, MN; Dahl, GV; Kshirsagar, S; Lacayo, NJ; Lum, BL; O'Brien, MM; Ravindranath, Y; Sikic, BI; Weinstein, H, 2010)
"This prospective phase II clinical trial evaluated the effects of single-dose mitoxantrone (36 mg/m2 on day 1) in combination with continuous infusion intermediate-dose cytarabine plus etoposide in 25 patients with refractory or early relapsed acute myeloid leukemia (AML)."	2.74	Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia. ( Chi, HS; Jang, S; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, SS; Lee, YS; Lim, SN; Park, CJ; Ryu, SG; Seol, M; Yun, SC, 2009)
"To observe the clinical efficacy of Chinese drugs combined with chemotherapy in the treatment of acute myeloid leukemia (AML) and to investigate the prognostic relevance of the main parameters in AML treated with integrative medicine."	2.74	Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy. ( Hu, NP; Hu, XM; Li, L; Liu, C; Liu, F; Ma, R; Wang, HZ; Xiao, HY; Xu, YG; Yang, XH; Zhang, SS; Zheng, CM, 2009)
"Gemcitabine was administered at 10 mg/m(2)/min for 3-15 h, fludarabine at 25 mg/m(2) daily for days 1-5 and mitoxantrone at 10 mg/m(2) daily on days 1-3."	2.73	Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia. ( Adams, DJ; Decastro, CM; Gockerman, JP; Moore, JO; Peterson, BL; Petros, WP; Rao, AV; Rizzieri, DA; Sand, GJ; Spasojevic, I; Younis, IR, 2008)
" Nine patients were enrolled at increasing dosage levels of ara-C (8, 12, and 16 g/m2 per dose level)."	2.73	Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG). ( Arai, Y; Doki, N; Ishida, F; Kano, Y; Kawai, Y; Komatsu, N; Miyawaki, S; Morii, T; Ogura, M; Ohno, R; Takeshita, A; Usui, N, 2007)
"Mitoxantrone is an anthracenedione, which is active in NHL and its toxicity profile may be more favorable than doxorubicin with respect to alopecia, mucositis and cardiotoxicity."	2.71	A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma. ( Angelopoulou, MK; Bourantas, KL; Christopoulos, G; Grigorakis, V; Kalmantis, T; Kokkinis, G; Korantzis, J; Michalis, E; Mihalakeas, I; Pangalis, GA; Papayiannis, A; Repousis, P; Roussou, P; Siakantaris, MP; Stamatellou, M; Stefanoudakis, E; Symeonidis, A; Vassilakopoulos, TP; Vrakidou, E, 2003)
"Primary resistant acute myeloid leukemia (AML) has a very poor prognosis."	2.71	Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors. ( Chelghoum, Y; Elhamri, M; Le, QH; Michallet, M; Revesz, D; Thomas, X, 2003)
" In this study, the efficacy of lintuzumab in combination with induction chemotherapy was compared with chemotherapy alone in adults with first relapsed or primary refractory acute myeloid leukemia (AML)."	2.71	Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. ( Brandwein, J; Brown, R; Chopra, R; De Angelo, D; Ehmann, WC; Feldman, EJ; Frankel, SR; Jurcic, JC; Kalaycio, M; Miller, C; Moore, J; O'Connor, J; Roboz, GJ; Scheinberg, D; Schulman, P; Stone, R; Wedel, N, 2005)
"Overall response rate was 31% in 26 acute myelogenous leukemia and 12."	2.71	Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. ( Bauer, KS; Bible, K; Briel, J; Colevas, AD; Garimella, TS; Gojo, I; Gore, SD; Greer, J; Karp, JE; Kaufmann, S; Passaniti, A; Ross, DD; Smith, BD; Tidwell, ML; Wright, JJ, 2005)
"All 35 patients were treated with the ANLL91 protocol consisting of etoposide, high-dose cytarabine, and anthracyclines."	2.70	Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group. ( Eguchi, M; Hayashi, Y; Hibi, S; Hongo, T; Imaizumi, M; Ishii, E; Isoyama, K; Kamada, N; Kawasaki, H; Kinukawa, N; Kosaka, Y; Mizutani, S; Nishimura, S; Oda, M; Oda, T; Okamura, T; Okawa, H; Tsukimoto, I, 2001)
" We conclude that CBP at a cumulative dosage of 1 g/m2 together with intercalating agents (IDA/MIT) has antileukemic efficacy in elderly patients."	2.69	Continuous-infusion carboplatin in combination with idarubicin or mitoxantrone for high-risk acute myeloid leukemia: a randomised phase II study. ( Archimbaud, E; Assouline, D; Belhabri, A; Blanc, M; Fière, D; Michallet, M; Thomas, X; Tigaud, JD; Troncy, J; Wattel, E, 1999)
"A total of 64 newly diagnosed acute myelogenous leukemia patients (except FAB M3 and/or Down syndrome) under 18 years of age were consecutively enrolled into the study."	2.69	Treatment of childhood acute myelogenous leukemia with allogeneic and autologous stem cell transplantation during the first remission: a report from the Kyushu-Yamaguchi Children's Cancer Study group in Japan. ( Anami, K; Ayukawa, H; Eguchi, H; Hara, T; Ikuno, Y; Inada, H; Ishii, E; Matsuzaki, A; Miyazaki, S; Nibu, K; Okamura, J; Sugimoto, T; Yanai, F, 2000)
"The CAG regimen seems promising for the treatment of relapsed AML with its low toxicity contributing to a high quality of life for the patient."	2.68	[Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia ( Aoyagi, A; Arimura, H; Furusawa, S; Koike, T; Noguchi, M; Saito, K; Sakuma, H; Waga, K; Yamada, K; Yamato, H, 1995)
"Mitoxantrone (M) is a synthetic aminoanthraquinone with anti-leukemic activity in patients with daunorubicin (D) resistant acute leukemia."	2.68	Sequential mitoxantrone, daunorubicin, and cytosine arabinoside for patients with newly diagnosed acute myelocytic leukemia. ( Cuttner, J; Davis, RB; Gottlieb, A; Holland, JF; Martelo, O; Paciucci, PA, 1997)
"193 patients with relapsed or refractory acute myeloid leukemia (AML) were entered into a prospective randomized comparison of high-dose versus intermediate dose cytosine arabinoside (AraC) both combined with mitoxantrone (mitox) according to the previously established sequential HD-AraC/mitox regimen (S-HAM)."	2.67	High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison. ( Aul, C; Balleisen, L; Bartholomäus, A; Becker, K; Bettelheim, P; Hiddemann, W; Lathan, B; Ludwig, WD; Maschmeyer, G; Schönrock-Nabulsi, R, 1993)
"Since January 1988, 91 children with ANLL have been treated with a polychemotherapy regimen containing Mitoxantrone (MTZ), excluding other anthracyclines."	2.67	Mitoxantrone and high dose Ara-C for the treatment of ANLL in childhood: a pilot study of the EORTC CLCG (EORTC 58 872). ( Babin, A; Béhar, C; Bertrand, Y; Boutard, P; Brock, P; Robert, A; Rubie, H; Solbu, G; Suciu, S; Vilmer, E, 1992)
"Mitoxantrone is a new anthracenodione derivative with a high antineoplastic activity in proliferative diseases of the haemopoietic system."	2.67	[Preliminary results of the treatment of acute leukemia with mitoxantrone]. ( Apel, D; Hołowiecki, J; Konecki, R; Lawniczek, T; Maj, S; Mariańska, B; Mazur, J; Pałynyczko, G; Rozmysłowicz, T; Rudzka, E, 1991)
"In the following study, patients with acute myeloid leukemia (AML) treated with double induction and consolidation chemotherapy (AML COOP study 1986, [3]) were randomized in a group with and without accompanying low-dose oral verapamil treatment."	2.67	Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial. ( Appelt, M; Büchner, T; Eichelbaum, M; Grille, W; Hiddemann, W; Hossfeld, DK; Koslowski, B; Kraft, J; Kuse, R; Quabeck, K, 1990)
"Mitoxantrone is an active agent in the treatment of acute leukemia and demonstrates incomplete cross resistance with duanorubicin."	2.67	Mitoxantrone for refractory and relapsed acute leukemia. ( Bernasconi, C; Bezwoda, WR; de Bock, R; Hutchinson, RM; Mandelli, F; Winfield, DA, 1990)
"Mitoxantrone is an intravenous anthracenedione structurally related to the anthracycline antibiotics."	2.40	Mitoxantrone in the treatment of acute myelogenous leukemia: a review. ( Archimbaud, E; Thomas, X, 1997)
"Mitoxantrone has also been effective in inducing complete remissions in patients with relapsed or refractory ANLL, mainly in combination with other antineoplastic agents."	2.39	Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia. ( Dunn, CJ; Goa, KL, 1996)
"Bacterial bloodstream infections were the most frequent followed by respiratory tract infections."	1.91	Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms. ( Boeckh, M; Cheng, GS; Chung, EL; Delaney, C; Halpern, AB; Hill, JA; Huebner, EM; Kiem, ES; Kimball, LE; Leisenring, WM; Liu, C; Pergam, SA; Schonhoff, KG; Walter, RB; Walti, CS; Xie, H, 2023)
"Relapsed or refractory acute myeloid leukemia (R/R AML) has a poor prognosis and is best treated with salvage chemotherapy as a bridge to allogeneic stem cell transplant (alloSCT)."	1.56	A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. ( Agrawal, V; Arain, S; Cahill, K; Calip, GS; Christian, S; Esen, A; Griffin, S; Khan, I; Konig, H; Odenike, O; Patel, P; Quigley, JG; Shergill, A; Stock, W; Sweiss, K, 2020)
"Primary refractory acute myeloid leukemia (AML) is associated with dismal prognosis."	1.56	Tandem Allogeneic Hematopoietic Stem Cell Transplantation for Salvage Treatment of Acute Myeloid Leukemia Refractory to Induction Chemotherapy: A Case Report. ( Basak, GW; Drozd-Sokolowska, J; Dwilewicz-Trojaczek, J; Gierej, B; Halaburda, K; Karakulska-Prystupiuk, E; Sachs, W; Tormanowska, M; Urbanowska, E; Wiktor-Jedrzejczak, W, 2020)
"However, the case of secondary chronic myeloid leukemia following acute myeloid leukemia treated with autologous hematopoietic stem cell transplantation is rare."	1.56	Secondary chronic myeloid leukemia following acute myeloid leukemia treated with autologous hematopoietic stem cell transplantation: a case report. ( Bin, T; Chen, S; Chen, X; Cheng, J; Liao, Y; OUYang, J; Zou, W, 2020)
"Azathioprine sodium use was observed more frequently in cases (odds ratio [OR], 7."	1.46	Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. ( Al-Kali, A; Castro, J; Dueck, A; Ertz-Archambault, N; Finn, L; Foran, J; Gauthier, S; Kelemen, K; Kosiorek, H; Marino, R; Mesa, RA; Palmer, J; Sproat, LZ; Taylor, GE; Tibes, R, 2017)
"Relapsed acute myeloid leukemia (AML) represents a major therapeutic challenge."	1.43	Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse. ( Agha, M; Amjad, A; Boyiadzis, M; Dorritie, KA; Duggal, S; Farah, R; Hou, JZ; Im, A; Lim, S; McLaughlin, B; Raptis, A; Redner, RL; Sehgal, A; Shuai, Y, 2016)
"Establishment of the acute myeloid leukemia cells SKM-1 and MOLM-13 for resistance by azacytidine (AzaC) resulted in SKM-1/AzaC and MOLM-13/AzaC cell variants with reduced sensitivity to AzaC."	1.42	Acute myeloid leukemia cells MOLM-13 and SKM-1 established for resistance by azacytidine are crossresistant to P-glycoprotein substrates. ( Breier, A; Imrichova, D; Kavcova, H; Messingerova, L; Sulova, Z; Turakova, K, 2015)
"To investigate the efficacy and safety of MA (mitoxantrone and cytarabine) regimen chemotherapy combined with granulocyte-colony stimulating factor (G-CSF)-mobilized family related HLA-haploidentical donor peripheral blood hematopoietic stem cell (G-PBHSC) infusion for the treatment of acute myeloid leukemia (AML) patients aged over 80 years."	1.42	[Clinical Analysis of 4 AML Patients Aged Over 80 Years Treated with Chemotherapy Combined with Haploidentical Hematopoietic Stem Cell Infusion]. ( Hu, HL; Huang, YJ; Li, J; Liu, J; Sun, WJ; Xi, XQ; Zhao, HX, 2015)
"For patients with acute myeloid leukemia from antecedent myelodysplastic syndrome particularly after azanucleoside treatment failure, outcome is poor."	1.40	Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. ( Al Ali, NH; Bello, CM; Duong, VH; Fernandez, HF; Jaglal, MV; Komrokji, RS; Lancet, JE; List, AF; Padron, E, 2014)
"Mortality of acute myeloid leukemia is still 60-70% in young (<60 years) adults and 90% in elderly (≥60 years) patients."	1.40	[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)]. ( Batár, P; Bedekovics, J; Hevessy, Z; Illés, A; Kiss, A; Márton, A; Pinczés, L; Rejtő, L; Reményi, G; Selmeczi, A; Szász, R; Telek, B; Udvardy, M; Ujfalusi, A; Ujj, Z, 2014)
"We investigated the time and site of recurrence, response to re-induction therapy, and performance of hematopoietic stem cell transplantation (HSCT) in relapsed cases, and performed a multivariate analysis to identify prognostic factors."	1.40	Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol. ( Adachi, S; Hamamoto, K; Hanada, R; Hayashi, Y; Horibe, K; Imaizumi, M; Kobayashi, R; Kudo, K; Miyamura, T; Morimoto, A; Moritake, H; Nakayama, H; Shimada, A; Tabuchi, K; Taga, T; Tawa, A; Tomizawa, D; Tsuchida, M; Tsukimoto, I; Yabe, H, 2014)
"A 23-year-old man with acute myelogenous leukemia (AML) (M2) who was pretreated with chemotherapy for autologous bone marrow transplantation developed a skin ulcer on the left groin."	1.39	Dermatic Scedosporium apiospermum infection after autologous bone marrow transplantation. ( Chen, H; Hu, J; Hu, L; Jiang, M; Li, B; Li, Y; Lou, X; Ning, H; Wang, J; Xu, C; Yu, Z, 2013)
"A drug-resistant acute myeloid leukemia cell line, HL60/MX2, also failed to acquire resistance to CXL017 upon chronic exposure and regained sensitivity toward standard therapies."	1.39	Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIβ downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia. ( Das, SG; Hermanson, DL; Li, Y; Xing, C, 2013)
"A disseminated Fusarium infection due to F."	1.39	Refractory disseminated fusariosis by Fusarium verticillioides in a patient with acute myeloid leukaemia relapsed after allogeneic hematopoietic stem cell transplantation: a case report and literature review. ( Bartolesi, AM; Fanci, R; Pecile, P; Pini, G, 2013)
" Herein, we report the response to treatment with a fixed dosing schedule of ME or MEC in 65 patients treated for primary refractory or relapsed AML with intermediate or unfavorable risk cytogenetics."	1.38	Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia. ( Altman, J; Carlson-Leuer, K; Coyle, K; Frankfurt, O; Mehta, J; Newman, D; Rademaker, AW; Tallman, MS; Trifilio, SM, 2012)
"The most effective regimen for acute myeloid leukemia (AML) patients who do not achieve complete remission (CR) after two different courses of front-line chemotherapy has not been established."	1.37	Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy. ( Agha, M; Boyiadzis, M; Duggal, S; Foon, KA; Hou, JZ; Luong, TM; Mehta, DR; Raptis, A; Redner, RL; Schlesselman, JJ, 2011)
"Patients with core binding factor acute myeloid leukemia (CBF-AML) benefit from more intensive chemotherapy, but whether both the t(8;21) and inv(16)/t (16;16) subtypes requires intensification remained to be determined."	1.37	Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). ( Bourquin, JP; Corbacioglu, S; Creutzig, U; Dworzak, MN; Reinhardt, D; Sander, A; Schrauder, A; Stary, J; Teigler-Schlegel, A; von Neuhoff, C; Zimmermann, M, 2011)
"Twelve years after the diagnosis of acute myeloid leukemia, and following a viral infection of an unknown cause, he developed symptoms of heart failure."	1.36	Heart transplant in a childhood leukemia survivor: a case report. ( Bubanska, E; Hrebik, M; Mladosievicova, B; Urbanova, D, 2010)
"The majority of patients with acute myeloid leukemia (AML) will require second-line chemotherapy for either relapsed or refractory disease."	1.36	Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience. ( Alizadeh, AA; Berube, C; Coutre, S; Gotlib, J; Ho, M; Kohrt, HE; Liedtke, M; Majeti, R; Medeiros, BC; Owen, T; Patel, S; Pollyea, DA, 2010)
"Aspergillosis is a common fungal infection in immunocompromised patients undergoing chemotherapy."	1.35	Localized small-bowel infarction caused by Aspergillus during chemotherapy for acute myeloid leukemia: report of a case. ( Enjoji, M; Hamaguchi, H; Kawachi, Y; Kurisu, A; Kusakabe, M; Maruyama, H; Matsuki, M; Nagano, H; Nagata, K; Ohtsukasa, S; Taki, K, 2008)
"This report describes a patient with Ollier disease and AML and may offer a clue into the genetic pathogenesis of these disorders."	1.35	Acute myelogenous leukemia associated with Ollier disease. ( Martin, PL; McLean, TW; White, MS, 2008)
"One hundred and ninety-six untreated de novo acute myeloid leukemia (AML) patients were treated with homoharringtonine + cytosine arabinoside (HA) based induction therapy composed of three chemotherapeutic drugs (HAD/M, D-daunorubicin-DNR, M-mitozantrone-MTZ) used in our hospital for the past 12 years."	1.35	Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype. ( Bian, S; Liu, S; Meng, Q; Mi, Y; Wang, J; Xue, Y; Yu, W; Zhao, Y, 2008)
" In vitro, CI-994 in combination with cytarabine (ara-C), daunorubicin and mitoxantrone, resulted in moderate synergism."	1.35	CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo. ( Comijn, EM; Hubeek, I; Kaspers, GJ; Merriman, RL; Padron, JM; Peters, GJ; Van der Wilt, CL, 2008)
"Mitoxantrone is a DNA topoisomerase II poison commonly used for the treatment of hormone-refractory prostate cancer."	1.34	Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer. ( Bouscary, D; Dômont, J; Goldwasser, F; Martinez, V; Mir, O, 2007)
"Fifty-seven patients with acute myelogenous leukemia (AML) received the following treatment in our hospital between May 1992 and April 2005."	1.34	[A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute]. ( Fujiwara, M; Higashimura, M; Izumi, N; Koike, T; Satou, N; Shibasaki, Y; Tsukada, N, 2007)
"A 28-year-old man with relapsed acute myelogenous leukemia (AML-M2) had undergone a non-myeloablative allogeneic peripheral stem cell transplantation."	1.33	Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone. ( Kara, B; Kara, IO; Paydas, S; Sahin, B, 2005)
"Standard practice in older patients with acute myeloid leukemia (AML) is induction chemotherapy (ICT) followed by post-remission chemotherapy (PRT)."	1.33	The role of post-remission chemotherapy for older patients with acute myelogenous leukemia. ( Abou-Jawde, RM; Advani, A; Kalaycio, M; Pohlman, B; Rybicki, L; Sekeres, M; Sobecks, R, 2006)
"From 1998 to 2001, 5 consecutive cases of AML/TMDS entered our hospital and achieved complete remission (CR) with continuous drip infusion of low-dose etoposide and low-dose Ara-C combined with mitoxantrone (MEtA regimen)."	1.32	[Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)]. ( Furukawa, Y; Kitani, T; Shibano, M; Tsukaguchi, M, 2004)
"Treatment with ciprofloxacin and gamma-globulin dramatically improved the patient's clinical features."	1.32	[Pseudomonas sepsis with ecthyma gangrenosum in an acute myeloid leukemia patient]. ( Komatsu, N; Mori, M; Nagai, T; Obara, Y; Ohmine, K; Ozawa, K; Toshima, M, 2004)
"We report a patient suffering from acute nonlymphocytic leukemia (ANLL) 3 years after treatment for stage IV ovarian cancer began."	1.31	Secondary acute nonlymphocytic leukemia following successful chemotherapy combining cisplatin, doxorubicin, and cyclophosphamide for stage IV epithelial ovarian cancer. ( Fujii, S; Fukushi, Y; Futagami, M; Higuchi, T; Saito, Y; Sakamoto, T; Sato, S; Takami, H; Yokoyama, Y, 2000)
"The prognosis for DS acute myeloid leukemia (AML) is better than for non-DS AML, but the clinical outcome of DS acute lymphoblastic leukemia (ALL) is equal to that of non-DS ALL."	1.31	Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. ( Creutzig, U; de Vries, E; Hählen, K; Huismans, DR; Janka-Schaub, GE; Jansen, G; Kaspers, GJ; Peters, GJ; Pieters, R; Rots, MG; van Zantwijk, CH; Veerman, AJ; Zwaan, CM, 2002)
"However, minimal residual disease (MRD) detected with DEK/CAN chimeric m-RNA by reverse transcription polymerase chain reaction (RT-PCR) was continuously observed, although decreased quantitatively, following several courses of consolidation and intensification chemotherapies."	1.30	[The detection of minimal residual disease by DEK/CAN chimeric m-RNA in a case of AML M2 with translocation t(6;9) (p23;q34) after chemotherapy and peripheral blood stem cell transplantation]. ( Ando, T; Ariyoshi, K; Hikiji, K; Kobayashi, M; Shinohara, K; Toyosawa, M, 1997)
"Severe infections are a major problem in patients suffering from acute nonlymphocytic leukemia (ANLL) undergoing myeloablative chemotherapy."	1.30	Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia. ( Diehl, V; Engert, A; Hegener, K; Hübel, K; Mansmann, G; Oberhäuser, F; Schnell, R; Staib, P, 1999)
"mitoxantrone was effective as the first line anti-tumor drug with other chemical agents in treating adult acute myeloid leukemia, its side-effects were mild."	1.30	[A study of mitoxantrone with other chemical agents in treating 126 cases of adult acute myeloid leukemia]. ( Chen, Y; Du, X; Fu, J; Lu, D; Qiu, J; Wang, D, 1999)
"The majority of patients with acute myeloid leukemia (AML) are elderly, and their response to chemotherapy is poorer than that of younger patients."	1.29	Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients. ( Amess, JA; Davis, CL; Gupta, RK; Leahy, M; Lim, J; Love, S; MacCallum, PK; Oza, AM; Rohatiner, AZ; Whelan, JS, 1995)
"Fifty patients with previously untreated acute myeloid leukemia were treated with an induction regimen consisting of cytosine arabinoside 100 mg/m2 per day by 18 h i."	1.29	Intensive consolidation chemotherapy for newly diagnosed acute myeloid leukemia using a regime containing moderate dose cytosine arabinoside and mitoxantrone. ( Chan, CH; Chan, J; Chan, LC; Chan, TK; Chiu, E; Chu, YC; Kwong, YL; Liang, R; Lie, A; Yeung, YM, 1995)
"Samples from 31 patients with acute myelocytic leukemia (AML) were tested with continuous drug exposure."	1.29	Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia. ( Fridborg, H; Killander, A; Kristensen, J; Larsson, R; Liliemark, J; Nygren, P; Oberg, G; Simonsson, B, 1994)
"Among 15 patients with acute lymphoblastic leukemia (ALL), complete remission was obtained in 5 patients (33."	1.29	Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia. ( Atamer, MA; Büyükkeçeci, F; Keskin, A; Tombuloğlu, M, 1994)
"Information about elderly patients with acute lymphoblastic leukemia is scarce."	1.28	[Treatment of elderly patients with hematological malignancies]. ( Mizoguchi, H; Saito, H, 1992)
"Neutrophilic eccrine hidradenitis (NEH) is a neutrophilic dermatosis primarily affecting the eccrine glands, and most commonly seen in patients undergoing chemotherapy for treatment of a malignancy."	1.28	Recurrent neutrophilic eccrine hidradenitis. ( Bernstein, EF; Spielvogel, RL; Topolsky, DL, 1992)
"Pulmonary complications of acute myelogenous leukemia are attributed to infection, hemorrhage, or toxicity from chemotherapeutic agents."	1.28	Pulmonary complications of acute myelogenous leukemia. ( Decter, J; Karetzky, MS; O'Donnell, T, 1992)
"Thirty-two patients with refractory acute myeloid leukemia (AML) received salvage therapy with a single course of mitoxantrone 6 mg/m2 intravenous (IV) bolus, etoposide 80 mg/m2 IV for a period of 1 hour, and cytarabine (Ara-C) 1 g/m2 IV for a period of 6 hours daily for 6 days (MEC)."	1.28	Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. ( Amadori, S; Arcese, W; Isacchi, G; Mandelli, F; Meloni, G; Monarca, B; Petti, MC; Testi, AM, 1991)
"In order to reduce the incidence of severe complications noted with regimens containing high-dose cytarabine (HD ARA-C), wer used a combination of mitoxantrone (MTZ) in optimal dosage (12 mg/m2/day for 5 days) and cytarabine in intermediate dosage (1 g/m2 twice daily for 3 or 5 days)."	1.28	Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia. ( Brière, J; Desablens, B; Ghandour, C; Harousseau, JL; Milpied, N, 1990)
"Leukemic pericardial effusion with cardiac tamponade in very rare as an initial manifestation of AML."	1.28	[Cardiac tamponade as an initial manifestation of acute myeloblastic leukemia]. ( Harada, M; Kawasaki, M; Kikuchi, Y; Niho, Y; Sata, T; Yamano, Y, 1990)
"Mitoxantrone is a substituted anthraquinone with considerable activity against human acute leukemia."	1.28	Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia. ( Choi, KE; Daley, KM; Kaminer, LS; Larson, RA, 1990)
"9 patients had acute myeloblastic leukemia (AML), (4 relapsed, 5 refractory), 20 had acute lymphoblastic leukemia (ALL) (11 relapsed, 9 refractory) and 6 had chronic myelogenous leukemia (CML) in the blastic phase (BP)."	1.28	High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients. ( Carcassonne, Y; Gastaut, JA; Launay, MC; Lejeune, C; Maraninchi, D; Richard, B; Sainty, D; Sebahoun, G; Tubiana, N, 1990)
" The dosage of diaziquone was increased for sequential cohorts of seven patients from 20 mg/m2/day to 24 mg/m2/day, and finally to 28 mg/m2/day to determine the maximum tolerated dose for this chemotherapy combination."	1.28	Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study. ( Amrein, PC; Davis, RB; Mayer, RJ; Schiffer, CA, 1990)
"Mitoxantrone is a new effective antineoplastic agent with activity against a wide range of tumors."	1.28	Accidental overdose of mitoxantrone in three patients. ( Büchner, T; Essink, M; Hiddemann, W; Huhn, D; Jung, M; Koppensteiner, R; Marosi, L; Martin, T; Minar, E; Siegert, W, 1989)
"However, cardiac failure, the primary cause of death in four patients, was associated with coagulative fiber necroses and contraction band necroses, which may be related to acute cyclophosphamide toxicity."	1.27	Cardiac damage in autologous bone marrow transplant patients: an autopsy study. Cardiotoxic pretreatment as a major risk factor. ( Dörken, B; Körbling, M; Mall, G; von Herbay, A, 1988)
"The three patients with acute lymphocytic leukemia did not achieve CR."	1.27	A new combination of two intercalating agents (mitoxantrone + daunomycin) in adult refractory acute leukemia: the DON protocol. ( Gorin, NC; Isnard, F; Laporte, JP; Lemonnier, MP; Najman, A, 1988)
"Mitoxantrone was 10-20 fold more potent against AML cells than ametantrone."	1.27	Comparison of mitoxantrone and ametantrone in human acute myelocytic leukemia cells in culture and in bone marrow granulocyte-macrophage progenitor cells. ( Fountzilas, G; Holland, JF; Mindich, B; Ohnuma, T; Rammos, K, 1986)
"Thirty-eight patients with acute myeloid leukemia (AML) were treated with mitoxantrone (Mto) combined with cytarabine (Ara-C)."	1.27	Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia. ( Brito-Babapulle, F; Catovsky, D; Galton, DA; Goldman, JM; Marcus, RE; Newland, AC; Slocombe, G, 1987)
"Mitoxantrone is a synthetic aminoanthraquinone we have previously reported to be effective for patients with acute leukemia in relapse."	1.27	Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia. ( Cuttner, J; Dutcher, JP; Holland, JF; Paciucci, PA; Strauman, JJ; Wiernik, PH, 1987)

Research

Studies (425)

Authors

Clinical Trials (34)

Trial Overview

Trial Outcomes

Number of Participants Experiencing Dose Limiting Toxicities (DLTs) at the Maximum Tolerated Dose (MTD) for Decitabine When Given Together With G-CLAM Toxicities (DLTs) (Phase I)

Timeframe	Studies, this research(%)	All Research%
pre-1990	46 (10.82)	18.7374
1990's	127 (29.88)	18.2507
2000's	107 (25.18)	29.6817
2010's	119 (28.00)	24.3611
2020's	26 (6.12)	2.80

Authors	Studies
DeAngelo, DJ	3
Jonas, BA	1
Liesveld, JL	1
Bixby, DL	1
Advani, AS	2
Marlton, P	1
Magnani, JL	1
Thackray, HM	1
Feldman, EJ	5
O'Dwyer, ME	1
Becker, PS	6
Mühleck, R	1
Scholl, S	3
Hilgendorf, I	2
Schrenk, K	1
Hammersen, J	1
Frietsch, JJ	1
Fleischmann, M	2
Sayer, HG	1
Glaser, A	1
Hochhaus, A	3
Schnetzke, U	2
Zeidner, JF	3
Lin, TL	1
Vigil, CE	1
Fine, G	1
Yair Levy, M	1
Nazha, A	2
Esteve, J	1
Lee, DJ	1
Yee, K	1
Dalovisio, A	1
Wang, ES	2
Bergua Burgues, JM	1
Schriber, J	1
Litzow, MR	4
Frankfurt, O	2
Castillo, TBD	1
Bhatt, VR	1
Bhatnagar, B	2
Mehta, P	1
Dillon, R	1
Vicente, MV	1
Anthony, S	1
Bearss, D	1
Montesinos, P	1
Douglas Smith, B	1
Anderson, R	1
Miller, LD	1
Isom, S	2
Chou, JW	1
Pladna, KM	1
Schramm, NJ	1
Ellis, LR	2
Howard, DS	1
Bhave, RR	1
Manuel, M	2
Dralle, S	2
Lyerly, S	2
Powell, BL	2
Pardee, TS	2
Walti, CS	3
Halpern, AB	9
Xie, H	3
Kiem, ES	2
Chung, EL	3
Schonhoff, KG	3
Huebner, EM	5
Delaney, C	2
Liu, C	4
Pergam, SA	3
Cheng, GS	3
Kimball, LE	3
Leisenring, WM	3
Boeckh, M	3
Walter, RB	10
Hill, JA	3
Niederwieser, D	2
Lang, T	1
Krahl, R	1
Heinicke, T	1
Maschmeyer, G	12
Al-Ali, HK	1
Schwind, S	1
Jentzsch, M	1
Cross, M	1
Kahl, C	1
Wolf, HH	1
Sayer, H	1
Schulze, A	2
Dreger, P	1
Hegenbart, U	1
Krämer, A	3
Junghanss, C	1
Mügge, LO	1
Hähling, D	1
Hirt, C	1
Späth, C	1
Peter, N	2
Opitz, B	1
Florschütz, A	1
Reifenrath, K	1
Zojer, N	1
Pönisch, W	2
Heyn, S	1
Vucinic, V	1
Aul, C	8
Giagounidis, A	2
Balleisen, L	5
Oldenkott, B	1
Staib, P	7
Kiehl, M	1
Schütte, W	1
Naumann, R	1
Eimermacher, H	2
Dörken, B	2
Sauerland, C	3
Lengfelder, E	10
Hiddemann, W	27
Wörmann, B	7
Müller-Tidow, C	3
Serve, H	6
Schliemann, C	2
Hehlmann, R	2
Berdel, WE	10
Pfirrmann, M	1
Krug, U	4
Hoffmann, VS	1
Lindsay, J	1
Greenwood, M	1
Chen, SC	1
Kong, DCM	1
Slavin, MA	1
Fredricks, DN	1
Kopmar, NE	1
Gooley, T	1
Curley, N	1
Russell, K	1
Shaw, C	1
Schonhoff, K	1
Lim, J	4
Scott, BL	5
Appelbaum, J	1
Hendrie, PC	5
Estey, EH	8
Percival, MM	6
Atchley, E	1
Weis, TM	1
Derkach, A	1
Galera, PK	1
Xiao, W	1
Glass, J	1
DeWolf, S	1
Roshal, M	1
Shah, R	1
Stump, SE	1
Rodríguez-Arbolí, E	1
Othus, M	8
Garcia, KA	1
Cassaday, RD	2
Oehler, VG	3
Appelbaum, JS	1
Abkowitz, JL	1
Orozco, JJ	2
Keel, SB	1
Ghiuzeli, MC	1
Pluta, A	2
Robak, T	3
Brzozowski, K	1
Stepka, K	1
Wawrzyniak, E	2
Krawczynska, A	1
Czemerska, M	1
Szmigielska-Kaplon, A	1
Grzybowska-Izydorczyk, O	1
Nowicki, M	1
Stelmach, P	1
Kuydowicz, M	1
Gromek, T	1
Hus, M	1
Helbig, G	1
Grosicki, S	2
Bodzenta, E	1
Razny, M	1
Wojcik, K	1
Bolkun, L	1
Kloczko, J	1
Knopinska-Posluszny, W	1
Piekarska, A	1
Hellman, A	1
Sobas, M	1
Wrobel, T	1
Patkowska, E	1
Lech-Maranda, E	1
Warzocha, K	2
Holowiecki, J	1
Giebel, S	2
Wierzbowska, A	3
Garcia, JS	1
Bhatt, S	1
Fell, G	1
Sperling, AS	2
Burgess, M	1
Keshishian, H	1
Yilma, B	1
Brunner, A	1
Neuberg, D	2
Carr, SA	1
Ebert, BL	2
Ballen, K	1
Stone, RM	3
Medeiros, BC	2
Letai, A	1
Narayan, R	1
Blonquist, TM	1
Emadi, A	1
Hasserjian, RP	1
Burke, M	1
Lescinskas, C	1
Neuberg, DS	1
Brunner, AM	2
Hobbs, G	1
Hock, H	1
McAfee, SL	1
Chen, YB	1
Attar, E	1
Graubert, TA	1
Bertoli, C	1
Moran, JA	1
Bergeron, MK	1
Foster, JE	1
Ramos, AY	1
Som, TT	1
Vartanian, MK	1
Story, JL	1
McGregor, K	1
Macrae, M	1
Behnan, T	1
Wey, MC	1
Rae, J	1
Preffer, FI	1
Lesho, P	1
Duong, VH	2
Mann, ML	1
Ballen, KK	2
Connolly, C	1
Amrein, PC	3
Fathi, AT	2
Scheckel, CJ	1
Meyer, M	1
Betcher, JA	1
Al-Kali, A	2
Foran, J	2
Palmer, J	2
Cahill, KE	1
Karimi, YH	1
Karrison, TG	1
Jain, N	1
Green, M	1
Weiner, H	1
Fulton, N	2
Kadri, S	1
Godley, LA	1
Artz, AS	1
Liu, H	2
Thirman, MJ	1
Le Beau, MM	1
McNerney, ME	1
Segal, J	1
Larson, RA	3
Stock, W	2
Odenike, O	2
Palmieri, R	2
Buckley, SA	3
Marconi, G	1
Talami, A	1
Abbenante, MC	1
Sartor, C	1
Parisi, S	1
Nanni, J	1
Bertamini, L	1
Ragaini, S	1
Olivi, M	1
de Polo, S	1
Cristiano, G	1
Fontana, MC	1
Bochicchio, MT	1
Ottaviani, E	1
Arpinati, M	1
Sessa, M	1
Baldazzi, C	1
Caso, L	1
Testoni, N	1
Baccarani, M	2
Bonifazi, F	1
Martinelli, G	1
Paolini, S	1
Cavo, M	1
Papayannidis, C	1
Curti, A	1
Christian, S	1
Arain, S	1
Patel, P	1
Khan, I	1
Calip, GS	1
Agrawal, V	1
Sweiss, K	1
Griffin, S	1
Cahill, K	1
Konig, H	1
Esen, A	1
Shergill, A	1
Quigley, JG	1
Drozd-Sokolowska, J	1
Dwilewicz-Trojaczek, J	1
Tormanowska, M	1
Karakulska-Prystupiuk, E	1
Sachs, W	1
Halaburda, K	1
Urbanowska, E	1
Gierej, B	1
Basak, GW	1
Wiktor-Jedrzejczak, W	1
Deng, L	1
Zhang, C	2
Ying, S	1
Cai, B	1
Zhou, F	1
Cheng, J	1
Liao, Y	1
Bin, T	1
OUYang, J	1
Chen, S	1
Chen, X	1
Zou, W	1
Godwin, CD	1
Tsui, SP	1
Ip, HW	1
Saw, NY	1
Cheung, AK	1
Ng, NK	1
Man, CH	1
Lam, SS	1
Tang, WF	1
Lin, CH	1
Cheng, GH	1
Au, CH	1
Ma, ES	1
Chan, TL	1
So, JC	1
Ng, MH	1
Cheng, KC	1
Wong, KF	1
Siu, LP	1
Yip, SF	1
Lin, SY	1
Lau, JS	1
Luk, TH	1
Lee, HK	1
Lau, CK	1
Kho, B	1
Sim, JP	1
Kwong, YL	3
Leung, SY	1
Javed, A	1
Leung, AY	1
Karagiannis, P	1
Alsdorf, W	1
Tallarek, AC	1
Blohm, ME	1
Oelrich, J	1
Waizenegger, JS	1
Wolschke, C	1
Hecher, K	1
Singer, D	1
Bokemeyer, C	1
Fiedler, W	2
Ruan, M	1
Liu, LP	1
Zhang, AL	1
Quan Qi, B	1
Liu, F	2
Liu, TF	1
Liu, XM	1
Chen, XJ	1
Yang, WY	1
Guo, Y	1
Zhang, L	2
Zou, Y	1
Chen, YM	1
Zhu, XF	1
Przespolewski, A	1
Muppidi, MR	1
Freyer, CW	1
Ji, W	1
Cronin, TL	1
Thota, S	1
Griffiths, EA	1
Thompson, JE	1
Ontiveros, EP	1
Baron, J	1
Elshoury, A	1
Pogosova-Agadjanyan, EL	1
Orlowski, KF	2
Chen, TL	3
Stirewalt, DL	2
Alexander, TB	1
Wang, L	1
Inaba, H	1
Triplett, BM	1
Pounds, S	1
Ribeiro, RC	1
Pui, CH	1
Rubnitz, JE	1
Rashidi, A	1
Ali, AM	1
Vij, KR	1
Shanley, R	1
Romee, R	1
Cooley, SA	1
Westervelt, P	3
DiPersio, JF	3
Miller, JS	1
Weisdorf, DJ	1
Ustun, C	1
Werner, L	1
Avigan, D	1
Washington, A	1
Stroopinsky, D	1
Rosenblatt, J	1
McMasters, M	1
Luptakova, K	1
Wadleigh, M	1
Steensma, DP	1
Hobbs, GS	1
Attar, EC	1
Röllig, C	4
Kramer, M	4
Gabrecht, M	1
Hänel, M	4
Herbst, R	3
Kaiser, U	1
Schmitz, N	3
Kullmer, J	1
Fetscher, S	1
Link, H	3
Mantovani-Löffler, L	1
Krümpelmann, U	1
Neuhaus, T	1
Heits, F	1
Einsele, H	2
Ritter, B	1
Bornhäuser, M	4
Schetelig, J	4
Thiede, C	4
Mohr, B	2
Schaich, M	4
Platzbecker, U	1
Schäfer-Eckart, K	4
Ehninger, G	11
Schuler, US	1
Rasche, M	1
Zimmermann, M	4
Borschel, L	1
Bourquin, JP	2
Dworzak, M	2
Klingebiel, T	1
Lehrnbecher, T	3
Creutzig, U	7
Klusmann, JH	1
Reinhardt, D	5
Kasner, MT	2
Mick, R	1
Jeschke, GR	1
Carabasi, M	1
Filicko-O'Hara, J	1
Flomenberg, N	1
Frey, NV	1
Hexner, EO	1
Luger, SM	3
Loren, AW	1
Mangan, JK	1
Wagner, JL	1
Weiss, M	1
Carroll, M	2
Perl, AE	2
Rose, A	1
Brayer, J	1
Wan Ariffin, E	1
Jones, H	1
Bhatnagar, N	1
Foster, MC	2
Blackford, AL	2
Morris, LE	2
Strickland, SA	2
Lancet, JE	4
Bose, P	2
Levy, MY	2
Tibes, R	3
Gojo, I	5

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia[NCT02306291]	Phase 1/Phase 2	91 participants (Actual)	Interventional	2015-03-31	Completed
An Open Label Study to Evaluate the Feasibility of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)[NCT02484391]	Phase 2	50 participants (Anticipated)	Interventional	2015-09-30	Completed
Evaluation of the Efficacy of Induction-consolidation Treatment Using a Double Induction in Patients With AML <60 Years Old, Depending on the Percentage of Blasts in the 14 Day, Residual Disease and Leukemic Hematopoietic Cells[NCT02072811]	Phase 3	400 participants (Anticipated)	Interventional	2014-02-28	Recruiting
Phase I Trial of Brentuximab Vedotin With Re-induction Chemotherapy in Patients With Relapsed, CD30 Expressing, Acute Myeloid Leukemia (AML)[NCT01830777]	Phase 1	22 participants (Actual)	Interventional	2013-05-31	Completed
Phase I Investigation of the Feasibility of Combining 5-azacytidine With Highdose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy in a Sequential Manner for Remission Induction in High-risk Acute Myelogenous Leukemia (AML)[NCT01839240]	Phase 1	50 participants (Actual)	Interventional	2012-06-06	Completed
Phase 1/2 Study of Concurrent Decitabine in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)[NCT02921061]	Phase 1/Phase 2	28 participants (Actual)	Interventional	2016-11-17	Completed
AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study.[NCT00180102]	Phase 4	600 participants (Anticipated)	Interventional	2003-12-31	Completed
Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML[NCT02686593]	Phase 2	50 participants (Actual)	Interventional	2016-02-01	Completed
Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial[NCT05628623]	Phase 2	184 participants (Anticipated)	Interventional	2023-10-23	Not yet recruiting
Risk-stratified Therapy for Primary and Secondary AML and MDS. A Randomized Study by AMLCG in Relation to Cytogenetically Defined Prognostic Factors (1) on the Role of High-dose AraC as Part of Double Induction, (2) on G-CSF Priming, and (3) on High-dose [NCT00266136]	Phase 3	3,500 participants (Actual)	Interventional	1999-06-30	Completed
Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance[NCT01587430]	Phase 4	245 participants (Anticipated)	Interventional	2010-01-31	Active, not recruiting
"Randomized Phase II Trial of Timed Sequential Therapy (TST) With Alvocidib (Flavopiridol), Ara-C and Mitoxantrone (FLAM) vs. 7+3 for Adults Age 70 and Under With Newly Diagnosed Acute Myelogenous Leukemia (AML)"[NCT01349972]	Phase 2	172 participants (Actual)	Interventional	2011-04-30	Completed
Phase I Study of the Combination of Midostaurin, Bortezomib, and Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia[NCT01174888]	Phase 1	34 participants (Actual)	Interventional	2010-08-31	Completed
Multicenter Therapy-Optimization Trial AML-BFM 2004 for the Treatment of Acute Myeloid Leukemias in Children and Adolescents[NCT00111345]	Phase 2/Phase 3	550 participants (Actual)	Interventional	2004-03-31	Active, not recruiting
Phase II Study on Gemtuzumab Ozogamicin in Combination With All-trans-Retinoic Acid, High-dose Cytarabine and Mitoxantrone in Patients With Primary Refractory Acute Myeloid Leukemia[NCT00143975]	Phase 2	95 participants (Actual)	Interventional	2004-06-30	Completed
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia[NCT01822015]	Early Phase 1	55 participants (Actual)	Interventional	2013-03-15	Completed
ACUTE MYELOID LEUKAEMIA TRIAL 12[NCT00002658]	Phase 3	2,000 participants (Anticipated)	Interventional	1994-01-31	Active, not recruiting
A PHASE I COOPERATIVE AGREEMENT PEDIATRIC TRIAL OF MITOXANTRONE, ETOPOSIDE AND PSC-833 (PSC-ME) THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY ACUTE LEUKEMIA[NCT00002912]	Phase 1	3 participants (Actual)	Interventional	1997-01-31	Completed
an Single Center，Single Arm, Phase 3 Study to Evaluate Efficacy and Safety of PD-1 Inhibitor Combined With Azacytidine and HAG Regimen for Patients With Relapsed or Refractory Acute Myeloid Leukemia.[NCT04722952]	Phase 3	30 participants (Anticipated)	Interventional	2021-05-01	Recruiting
Feasibility Study of the Use of Intermediate Doses of Cytarabine Associated With Autologous Hematopoietic Stem Cells as Consolidation Treatment of Young Adults With Low- or Intermediate-risk de Novo Acute Myeloid Leukemia[NCT03023384]		547 participants (Anticipated)	Observational [Patient Registry]	2016-12-31	Recruiting
Chemo Sensitization Before Hematopoietic Stem Cell Transplantation With a CXCR4 Antagonist in Patients With Acute Leukemia in Complete Remission: Pilot Study[NCT02605460]	Phase 2	20 participants (Anticipated)	Interventional	2014-02-28	Recruiting
A Phase I/II Study of AMD3100 With Mitoxantrone, Etoposide and Cytarabine (AMD3100+MEC) in Relapsed or Refractory AML[NCT00512252]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2007-07-31	Completed
A Phase IV, Randomized Study to Evaluate the Safety and Efficacy of Idarubicin at Different Dosages Combined With Cytarabine as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia[NCT02277847]	Phase 4	400 participants (Anticipated)	Interventional	2010-03-31	Enrolling by invitation
Phase II Study of Alvocidib (NSC 649890, Flavopiridol) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias[NCT00407966]	Phase 2	45 participants (Actual)	Interventional	2006-10-31	Completed
Phase 2 Study of Autologous Hematopoietic Cell Transplantation for Core-binding Factor Positive Acute Myeloid Leukemia in the First Complete Remission[NCT01050036]		39 participants (Anticipated)	Interventional	2010-01-31	Recruiting
A Prospective, Phase II Trial of Intravenous Bevacizumab (Avastin) for the Prevention of Recurrent Malignant Ascites[NCT00908219]	Phase 2	0 participants (Actual)	Interventional	2009-07-31	Withdrawn (stopped due to Accrual closed by sponsor due to lack of accrual and study progress)
IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY[NCT00002517]	Phase 3	0 participants	Interventional	1993-03-31	Completed
Adjuvant Androgen Deprivation Versus Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High-Risk Prostate Cancer Patients Following Radical Prostatectomy[NCT00004124]	Phase 3	983 participants (Actual)	Interventional	1999-10-15	Completed
Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia[NCT01690065]	Phase 2	46 participants (Anticipated)	Interventional	2012-09-30	Recruiting
A Pilot Study of Low Dose Melphalan and Bortezomib for Treatment of Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndromes[NCT00789256]		26 participants (Actual)	Interventional	2004-09-30	Completed
Multicenter Protocol in Treating Patients With Childhood Acute Myeloid Leukemia. Randomized Study of Maintenance Treatment With Interleukin-2[NCT00149162]	Phase 3	580 participants (Anticipated)	Interventional	2005-03-31	Recruiting
A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With RAEB-1 AND RAEB-2 Myelodysplastic Syndrome (MDS) and AML With Trisomy 8[NCT00533416]	Phase 1	14 participants (Actual)	Interventional	2007-09-14	Completed
A Study of the Safety of CMA-676 in Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) in First Relapse[NCT00003673]	Phase 2	55 participants (Anticipated)	Interventional	1998-03-31	Completed
A Study of the Efficacy and Safety of CMA-676 as Single Agent Treatment of Patients With Acute Myeloid Leukemia (AML) in First Relapse[NCT00003131]	Phase 2	55 participants (Anticipated)	Interventional	1997-02-28	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"Evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. MTD is defined as the highest dose studied in which the incidence of DLT is < 33%. Each participant was monitored for DLTs in the first 20 days of treatment. DLTs monitored included~any grade 3 non-hematologic toxicity lasting more than 48 hours that resulted in more than a 7 day delay of the subsequent treatment cycle (except for febrile neutropenia or infection)~any grade 4 or greater non-hematologic toxicity (except febrile neutropenia and infection unless a direct consequence of a treatment-related toxicity, and except constitutional symptoms if they recovered to grade 2 or less within 14 days)~lack of recovery of the absolute neutrophil count to 500/microliter or greater and lack of self-sustained platelet count of at least 50,000/microliter by treatment day +49 with no evidence of residual leukemia" (NCT02921061)
Timeframe: Up to 49 days

Number of Participants Who Achieved Remission (Complete Remission [CR]/CR With Incomplete Peripheral Blood Count Recovery [CRi])

Number of Participants With Event-free Survival

Number of Participants With Minimal Residual Disease Negative (MRDneg) Complete Remission (Phase II)

Intervention	Participants (Count of Participants)
Treatment (Decitabine 20 mg/m2 and G-CLAM)	3

Intervention	participants (Number)
Treatment (Decitabine 20 mg/m2 and G-CLAM)	13

Intervention	participants (Number)
Treatment (Decitabine 20 mg/m2 and G-CLAM)	8

Compared to historical controls of filgrastim, cladribine, cytarabine, and mitoxantrone hydrochloride (G-CLAM) alone. A Simon Minimax two-stage design will be used. (NCT02921061)
Timeframe: Up to 1 year

Number of Participants With Overall Survival

Number of Participants With Relapse-free Survival

Complete Response Rate

Intervention	participants (Number)
Treatment (Decitabine 20 mg/m2 and G-CLAM)	13

Intervention	participants (Number)
Treatment (Decitabine 20 mg/m2 and G-CLAM)	9

Intervention	participants (Number)
Treatment (Decitabine 20 mg/m2 and G-CLAM)	8

Bone marrow showing less than 5% myeloblasts with normal maturation of all cell lines, an ANC of at least 1000/cu mm and a platelet count of 100,000/cu mm, absence of blast in peripheral blood, absence of identifiable leukemic cells in the bone marrow, clearance of disease-associated cytogenetic abnormalities, and clearance of any previously existing extramedullary disease. These criteria are taken from Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-474 (NCT01349972)
Timeframe: 3 years

Disease-free Survival

Intervention	participants (Number)
Arm I (Alvocidib, Cytarabine, Mitoxantrone Hydrochloride)	76
Arm II (Cytarabine, Daunorubicin Hydrochloride)	24

Probabilities will be estimated with the Kaplan-Meier estimate. Survival estimates at two years will be estimated. Disease-free survival Overall survival was defined from date of randomization to death or last known follow-up. Event free survival was defined as date of randomization to the first occurrence of persistent AML after 1 cycle of induction, relapse or death. Patients were censored for event free survival if they had received non-protocol therapy or a stem cell transplant. (NCT01349972)
Timeframe: Time from randomization until death from any cause or relapse or recurrence, assessed up to 2 years

Incidence of Toxicities, Characterized by Number of Events by Treatment and Grade

Intervention	years (Median)
Arm I (Alvocidib, Cytarabine, Mitoxantrone Hydrochloride)	1.46
Arm II (Cytarabine, Daunorubicin Hydrochloride)	1.85

The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE reporting. (NCT01349972)
Timeframe: Up to 14 days after completion of study treatment

Number of Patients With Minimal Residual Disease

Intervention	Number of events (Number)
Arm I (Alvocidib, Cytarabine, Mitoxantrone Hydrochloride)	156
Arm II (Cytarabine, Daunorubicin Hydrochloride)	77

Comparisons of the treatments with respect to MRD will be based on the number of patients with MRD at day 14 after the start of treatment. (NCT01349972)
Timeframe: From study start to 14 days after the start of treatment

Overall Survival

Intervention	Participants (Count of Participants)
Arm I (Alvocidib, Cytarabine, Mitoxantrone Hydrochloride)	26
Arm II (Cytarabine, Daunorubicin Hydrochloride)	24

Probabilities will be estimated with the Kaplan-Meier estimate. Survival estimates at two years will be estimated. (NCT01349972)
Timeframe: 4 years

Progression-free Survival

Intervention	years (Median)
Arm I (Alvocidib, Cytarabine, Mitoxantrone Hydrochloride)	1.46
Arm II (Cytarabine, Daunorubicin Hydrochloride)	1.850

Probabilities will be estimated with the Kaplan-Meier estimate. Survival estimates at two years will be estimated. (NCT01349972)
Timeframe: 4 years

Overall Survival

Phase I Only: Optimal Dose of AMD3100 Plus MEC in Patients With Relapsed or Refractory AML

Intervention	years (Median)
Arm I (Alvocidib, Cytarabine, Mitoxantrone Hydrochloride)	0.81
Arm II (Cytarabine, Daunorubicin Hydrochloride)	0.28

Intervention	percentage of participants (Number)
Phase II Dose Treatment	37

A standard 3+3 design was used in the Phase I portion starting with the AMD3100 dose of 80 mcg/kg and escalating by 80 mcg/kg for each successive cohort up to a maximum of 240 mcg/kg/d. The optimal dose was defined as the highest dose of AMD3100 <= 240 mcg/kg at which 0-1 of 6 patients experienced a dose limiting toxicity. (NCT00512252)
Timeframe: Completion of all patients in Phase I portion (232 days)

Relapse-free Survival

Intervention	mcg/kg (Number)
Phase I Dose Escalation	240

"This is determined only for patients achieving a complete remission. Defined as the interval from the date of the first documentation of a leukemia free state to date of recurrence or death due to any cause.~Kaplain-Meier estimate was used." (NCT00512252)
Timeframe: 1 year

Time to Neutrophil Recovery

Intervention	percentage of participants (Number)
Phase II Dose Treatment	42.9

Defined as the date of the first dose of AMD3100 to the date that the absolute neutrophil count >1,000 cells/mm^3. (NCT00512252)
Timeframe: 42 days

Time to Platelet Recovery

Intervention	days (Median)
Phase II Dose Treatment	28

Defined as the date of the first dose of AMD3100 to the date that the platelet count is >100,000/mm3 in the absence of platelet transfusions. (NCT00512252)
Timeframe: 42 days

Characterize the Mobilization of Leukemic Cells With AMD3100 by Measuring the Peak Mobilization of AML Blasts (Phase I)

Intervention	days (Median)
Phase II Dose Treatment	28.5

Measured at 0 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, and 24 hours after AMD3100 dose on Day 0. (NCT00512252)
Timeframe: Day 0

Characterize the Mobilization of Leukemic Cells With AMD3100 by Measuring the Peak Mobilization of Total Leukocytes (Phase I)

Intervention	percentage of AML blasts (Median)
	AML blasts at 0 hours	AML blasts at 1 hour	AML blasts at 2 hours	AML blasts at 4 hours	AML blasts at 6 hours	AML blasts at 8 hours	AML blasts at 12 hours	AML blasts at 24 hours
Phase I Dose Escalation - Dose Level 1	46.0	26.0	26.0	37.0	31.0	32.0	27.0	35.0
Phase I Dose Escalation - Dose Level 2	4.0	9.0	37.5	16.0	14.0	19.0	45.0	23
Phase I Dose Escalation - Dose Level 3	43.5	30.5	32.5	30.0	27.0	26.0	35.0	55

"Measured at 0 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, and 24 hours after AMD3100 dose on Day 0.~Characterization of the mobilized cells as well as the kinetics of mobilization will be determined by analyzing the surface expression of mobilized cells by flow cytometry at the specified time points in conjunction with their total leukocyte count from the patient's CBC." (NCT00512252)
Timeframe: Day 0

Phase II Only: Complete Response Rate of AMD3100 + MEC

Intervention	cells x 10^3/microliter (Median)
	Total leukocytes at 0 hours	Total leukocytes at 1 hour	Total leukocytes at 2 hours	Total leukocytes at 4 hours	Total leukocytes at 6 hours	Total leukocytes at 8 hours	Total leukocytes at 12 hours	Total leukocytes at 24 hours
Phase I Dose Escalation - Dose Level 1	2.5	4.3	4	4.7	4.8	4.5	5.1	4.3
Phase I Dose Escalation - Dose Level 2	4.7	7.0	8.5	9.4	11.3	12.0	12.1	7.9
Phase I Dose Escalation - Dose Level 3	3.5	6.4	7.5	8.3	9.5	8.9	7.8	5.8

"Responses were assessed according to the International Working Group Criteria for AML. All patients who received at least one dose of AMD3100 were considered evaluable for response.~Response rate was the rate of complete remission plus complete remission with incomplete blood count recovery (CR + CRi)." (NCT00512252)
Timeframe: 42 days

Safety and Tolerability of AMD3100 + MEC.

Intervention	percentage of participants (Number)
	CR + CRi	CR only
>= Second Relapse/Salvage	25	25
First Relapse, First Salvage	56	47
Primary Refractory	20	20
Total	46	39

Treatment related mortality (deaths occurring during treatment) (NCT00512252)
Timeframe: 42 days

Treatment Failure

Intervention	participants (Number)
	Sepsis	Adverse transfusion reaction w/febrile neutropenia
Phase II Dose Treatment	2	1

Treatment failures includes those patients for whom treatment has failed to achieve a CR or a CRi. (NCT00512252)
Timeframe: 42 days

Complete Response

Intervention	participants (Number)
	Persistent leukemia	Death during aplasia	Unknown
>= Second Relapse/Salvage	3	0	0
First Relapse, First Salvage	12	1	1
Primary Refractory	6	2	0
Total	21	3	1

Bone marrow showing less than 5% myeloblasts with normal maturation of all cell lines, an Absolute Neutrophil Count of at least 1000/mililiter and a platelet count of 100,000 mililiter, absence of blast in peripheral blood, absence of identifiable leukemic cells in the bone marrow, clearance of disease-associated cytogenetic abnormalities, and clearance of any previously existing extramedullary disease. A complete remission must be confirmed 4 to 6 weeks after the initial documentation. If possible, at least one bone marrow biopsy should be performed to confirm the complete remission. (NCT00407966)
Timeframe: 6 months

Disease Free Survival

Intervention	participants (Number)
Arm A	45

Measured from date of randomization to date of first observation of recurrence or death due to any cause. Patients without recurrence are censored at date of last contact. (NCT00004124)
Timeframe: at 10 Years

Overall Survival

Intervention	percentage of probability of survival (Number)
Arm I: Bicalutamide + Goserelin	72
Arm II: Mitoxantrone + Prednisone + Bivalutamid + Goserelin	72

Measured from date of randomization to date of death from any cause. Patient known to be alive are censored at date of last contact. (NCT00004124)
Timeframe: at 10 Years

Compare Qualitative and Quantitative Toxicities of These Regimens in These Patients

Intervention	percentage of probability of survival (Number)
Arm I: Bicalutamide + Goserelin	87
Arm II: Mitoxantrone + Prednisone + Bivalutamid + Goserelin	86

Number of patients with adverse events that are related to study drug (NCT00004124)
Timeframe: Up to 22 months from registration

Response Rate of the Combination of Bortezomib and Melphalan in Patients With AML and High-risk MDS.

Intervention	Participants (Number)
	Abdominal pain/cramping	Abscess	Alkaline phosphatase increase	Allergic reaction	Allergic rhinitis	Alopecia	Anal incontinence	Anemia	Anorexia	Anxiety/agitation	Apnea	Arrhythmia, NOS	Arthralgia	Arthritis	Ataxia (incoordination)	Bilirubin increase	Blurred vision	Bone pain	Bruising	CPK increase	Cardiac ischemia/infarction	Cardiovascular-other	Cataract	Cerebrovascular ischemia	Chest pain,not cardio or pleur	Conduction abnormality/block	Confusion	Conjunctivitis	Constipation/bowel obstruction	Cough	Creatinine increase	Cushingoid appearance	Dehydration	Depression	Diarrhea without colostomy	Dizziness/light headedness	Dry eye	Dry skin	Dysmenorrhea	Dyspepsia/heartburn	Dyspnea	Dysuria	Ear-other	Edema	Endocrine-other	Epistaxis	Erectile impotence	Eryth/rash/eruption/desq, NOS	Esophagitis/dysphagia	Eye-other	Fatigue/malaise/lethargy	Febrile neutropenia	Feminization of male	Fever without neutropenia	Fever, NOS	Flatulence	Flu-like symptoms-other	Flushing	GGT increase	GI Mucositis, NOS	GI-other	GU-other	Gastritis
Arm I: Bicalutamide + Goserelin	19	0	11	1	2	91	2	52	7	52	1	0	43	17	1	5	3	19	1	0	1	0	5	1	11	1	6	0	57	10	7	0	0	80	55	33	1	11	0	7	21	14	0	40	3	0	181	0	2	1	258	0	1	0	1	2	2	5	1	0	12	9	2
Arm II: Mitoxantrone + Prednisone + Bivalutamid + Goserelin	41	1	11	5	16	131	2	141	41	62	1	1	64	17	1	20	6	34	14	2	1	5	6	0	19	0	14	4	117	34	17	8	6	85	75	71	5	28	1	44	49	11	2	56	2	2	146	2	13	6	357	2	0	9	6	3	6	4	0	10	20	9	0

Determine disease response to treatment using Cheson 2000 report of an international working group to standardize response criteria for myelodysplastic syndromes. (NCT00789256)
Timeframe: Post Cycle 1 through 28 days post-treatment

Article	Year
Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. Blood, 2022, 02-24, Volume: 139, Issue:8 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarab	2022
A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia. Blood cancer journal, 2021, 10-30, Volume: 11, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabi	2021
Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia. Nature communications, 2022, 03-30, Volume: 13, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Caprylates; Cytarabine; Humans; Leukemia, Myel	2022
Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms. Leukemia & lymphoma, 2023, Volume: 64, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, A	2023
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML. Blood advances, 2023, 09-12, Volume: 7, Issue:17 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Granulocyte Colony-St	2023
Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG). Leukemia & lymphoma, 2020, Volume: 61, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Humans; Leukemia, Mye	2020
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy. American journal of hematology, 2020, Volume: 95, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cytarabine; Etoposide; Femal	2020
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia. Cancer, 2020, 03-15, Volume: 126, Issue:6 Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B	2020
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood advances, 2020, 02-25, Volume: 4, Issue:4 Topics: Aged; Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Nucleophosmin; Remiss	2020
Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade Leukemia & lymphoma, 2020, Volume: 61, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Decitabine; Granulocy	2020
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study. Leukemia, 2017, Volume: 31, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers; Cytarabine; De	2017
Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials. Cancer, 2017, Oct-01, Volume: 123, Issue:19 Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplasti	2017
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. American journal of hematology, 2018, Volume: 93, Issue:2 Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposid	2018
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients. Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 04-01, Volume: 29, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; D	2018
Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition. Investigational new drugs, 2018, Volume: 36, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Mye	2018
Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML). Leukemia research, 2018, Volume: 72 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Flavo	2018
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study. Leukemia, 2018, Volume: 32, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabi	2018
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. American journal of hematology, 2019, Volume: 94, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival	2019
Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 01-01, Volume: 37, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Child; Child, Preschool; Daunorubici	2019
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms. Haematologica, 2019, Volume: 104, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Disease-Free Survival; Fema	2019
Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia. International journal of hematology, 2019, Volume: 109, Issue:4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival	2019
A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 07-15, Volume: 25, Issue:14 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cytarabine; Drug Resis	2019
Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy. Journal for immunotherapy of cancer, 2019, 07-10, Volume: 7, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cell	2019
Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: a phase 1/2 study. Leukemia & lymphoma, 2013, Volume: 54, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Drug Resistance, Multiple; Drug Resist	2013
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jun-10, Volume: 31, Issue:17 Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Ther	2013
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents. Annals of hematology, 2014, Volume: 93, Issue:8 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera	2014
Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia. Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:1 Topics: Adenine Nucleotides; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clof	2015
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer, 2015, Jan-15, Volume: 121, Issue:2 Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined	2015
The NPM1 mutation type has no impact on survival in cytogenetically normal AML. PloS one, 2014, Volume: 9, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Ge	2014
[Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results]. Terapevticheskii arkhiv, 2014, Volume: 86, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Dauno	2014
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL). Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:7 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administra	2015
Stromal CYR61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia. British journal of haematology, 2015, Volume: 170, Issue:5 Topics: Antineoplastic Agents; Cell Line, Tumor; Cysteine-Rich Protein 61; Drug Resistance, Neoplasm; Female	2015
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica, 2015, Volume: 100, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free	2015
Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004. Pediatric blood & cancer, 2016, Volume: 63, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; D	2016
Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia. Leukemia, 2016, Volume: 30, Issue:6 Topics: Adult; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Danazol; Disea	2016
Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy. Haematologica, 2016, Volume: 101, Issue:7 Topics: Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot	2016
A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia. Blood cancer journal, 2017, 03-10, Volume: 7, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Benzylamines; C	2017
Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia. American journal of hematology, 2008, Volume: 83, Issue:11 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cohort Studies; Combi	2008
Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia. Leukemia & lymphoma, 2008, Volume: 49, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Synergism; Female;	2008
Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia. Leukemia research, 2009, Volume: 33, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Kaplan	2009
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Nov-10, Volume: 26, Issue:32 Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens,	2008
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood, 2009, Apr-23, Volume: 113, Issue:17 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabi	2009
Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy. Chinese journal of integrative medicine, 2009, Volume: 15, Issue:3 Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplas	2009
Regimen containing perarubicin for the treatment of newly diagnosed young patients with acute myeloid leukemia. Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:6 Topics: Adolescent; Adult; Agranulocytosis; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cytara	2009
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leukemia research, 2010, Volume: 34, Issue:7 Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantatio	2010
Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-01, Volume: 28, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy	2010
Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-01, Volume: 28, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy	2010
Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-01, Volume: 28, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy	2010
Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-01, Volume: 28, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy	2010
Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group. Pediatric blood & cancer, 2010, Volume: 54, Issue:5 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfam	2010
Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy. Annals of hematology, 2011, Volume: 90, Issue:6 Topics: Adult; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Co	2011
Influence of anticancer therapy on oxidation phenotype and acetylation phenotype in patients with acute myeloblastic leukemia. Pharmacological reports : PR, 2011, Volume: 63, Issue:1 Topics: Acetylation; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytochrome P-4	2011
Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study. Pediatric blood & cancer, 2011, Jul-15, Volume: 57, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Disease-Free Survival;	2011
Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. Bone marrow transplantation, 2012, Volume: 47, Issue:4 Topics: Adult; Antineoplastic Agents; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell	2012
Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-01, Volume: 29, Issue:19 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetics; Disease	2011
Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. British journal of haematology, 2011, Volume: 155, Issue:3 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Consolidation C	2011
Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood, 2011, Dec-01, Volume: 118, Issue:23 Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents,	2011
Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Mar-15, Volume: 18, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedul	2012
A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia. Anticancer research, 2012, Volume: 32, Issue:2 Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Consolidatio	2012
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood, 2012, Apr-26, Volume: 119, Issue:17 Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamin	2012
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood, 2012, Apr-26, Volume: 119, Issue:17 Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamin	2012
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood, 2012, Apr-26, Volume: 119, Issue:17 Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamin	2012
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood, 2012, Apr-26, Volume: 119, Issue:17 Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamin	2012
Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report. Leukemia, 2013, Volume: 27, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; D	2013
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica, 2012, Volume: 97, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Fema	2012
Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy. International journal of hematology, 2012, Volume: 96, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury;	2012
High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission. Leukemia research, 2013, Volume: 37, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Surviva	2013
Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. Leukemia research, 2003, Volume: 27, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Human	2003
Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood, 2003, Aug-15, Volume: 102, Issue:4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter,	2003
A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma. Leukemia & lymphoma, 2003, Volume: 44, Issue:4 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disea	2003
Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Aug-01, Volume: 21, Issue:15 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabi	2003
Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors. Annals of hematology, 2003, Volume: 82, Issue:11 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administra	2003
Mitoxantrone and cytosine arabinoside in previously untreated adult patients with acute non-lymphocytic leukemia. Haematologia, 1996, Volume: 27, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cytar	1996
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by seq Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Dec-15, Volume: 21, Issue:24 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabi	2003
A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML. Leukemia research, 2004, Volume: 28, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Demography; Dis	2004
Priming with granulocyte colony-stimulating factor--relation to high-dose cytarabine in acute myeloid leukemia. The New England journal of medicine, 2004, May-20, Volume: 350, Issue:21 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabi	2004
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jun-01, Volume: 10, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetab	2004
A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia. Hematological oncology, 2004, Volume: 22, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Su	2004
Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine. Leukemia & lymphoma, 2005, Volume: 46, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Su	2005
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood, 2005, Jun-15, Volume: 105, Issue:12 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents;	2005
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-20, Volume: 23, Issue:18 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem	2005
Severe toxicity following induction chemotherapy for acute myelogenous leukemia in a patient with Werner's syndrome. Leukemia & lymphoma, 2005, Volume: 46, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA Helicases; Etoposide; Exodeox	2005
Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia. Leukemia research, 2006, Volume: 30, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Infusi	2006
Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report. Leukemia, 2005, Volume: 19, Issue:12 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Protocols; Bone Marrow Tr	2005
A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult L Cancer, 2005, Dec-15, Volume: 104, Issue:12 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; D	2005
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-01, Volume: 11, Issue:23 Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Ma	2005
Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution. Leukemia & lymphoma, 2006, Volume: 47, Issue:3 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Cytarabine; Diagnosis, Different	2006
Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group. Leukemia & lymphoma, 2006, Volume: 47, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Follow-U	2006
Flexible low-intensity combination chemotherapy for elderly patients with acute myeloid leukaemia: a multicentre, phase II study. Drugs & aging, 2007, Volume: 24, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Kaplan-	2007
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Aug-01, Volume: 13, Issue:15 Pt 1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Fema	2007
Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG). International journal of hematology, 2007, Volume: 86, Issue:4 Topics: Adult; Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Ef	2007
Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Proto	2008
Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. Seminars in oncology, 1984, Volume: 11, Issue:3 Suppl 1 Topics: Acute Disease; Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Antineoplastic Combin	1984
[Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia [Rinsho ketsueki] The Japanese journal of clinical hematology, 1995, Volume: 36, Issue:3 Topics: Aclarubicin; Adolescent; Adult; Aged; Cytarabine; Drug Administration Schedule; Drug Therapy, Combin	1995
Mitoxantrone, etoposide and ara-C vs doxorubicin-DNA, ara-C, thioguanine, vincristine and prednisolone in the treatment of patients with acute myelocytic leukaemia. A randomized comparison. European journal of haematology, 1995, Volume: 55, Issue:1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA Adducts; Doxorubi	1995
Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study. American journal of hematology, 1993, Volume: 43, Issue:4 Topics: Adult; Azacitidine; Biopsy; Blast Crisis; Bone Marrow; Cell Cycle; DNA, Neoplasm; Female; Humans; Ka	1993
Relation between platinum-DNA adducts and complete remission in adult acute nonlymphocytic leukemia. Leukemia research, 1994, Volume: 18, Issue:9 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Cyt	1994
Cytosine arabinoside and mitoxantrone induction chemotherapy followed by bone marrow transplantation or chemotherapy for relapsed or refractory pediatric acute myeloid leukemia. Leukemia, 1994, Volume: 8, Issue:10 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Chil	1994
[Role of double induction in the treatment of acute myeloblastic leukemia in the adult: intermediate results of protocol LAM90]. Nouvelle revue francaise d'hematologie, 1994, Volume: 36 Suppl 2 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Ac	1994
A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia. Annals of hematology, 1994, Volume: 69, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration	1994
Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON). Leukemia, 1994, Volume: 8, Issue:1 Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Respo	1994
Chemotherapy with high-dose cytosine arabinoside and mitoxantrone for poor-prognosis myeloid leukemias. Cancer investigation, 1993, Volume: 11, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedul	1993
Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Cr	1993
Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence. Leukemia, 1993, Volume: 7, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemi	1993
Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. Leukemia, 1993, Volume: 7, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cytarabine; Drug Admi	1993
High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison. Leukemia & lymphoma, 1993, Volume: 10 Suppl Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response	1993
Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia. Leukemia, 1996, Volume: 10, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide;	1996
Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study. Leukemia, 1996, Volume: 10, Issue:1 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C	1996
MEC (mitoxantrone, etoposide and intermediate dose cytarabine): an effective induction regimen for previously untreated acute non-lymphocytic leukemia. Leukemia & lymphoma, 1995, Volume: 19, Issue:5-6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug	1995
Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report. Zhonghua yi xue za zhi = Chinese medical journal; Free China ed, 1995, Volume: 56, Issue:5 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Gr	1995
Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin. Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:7 Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop	1996
[Treatment results for unselected patients with acute myelogenous leukemia. During a 10-year period, August 1984 to July 1994]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 1996, Volume: 37, Issue:9 Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Da	1996
Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience. Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:9 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation	1996
[Short-term intensive treatment for acute myelogenous leukemia (excluding M3 subtype) in adults]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 1997, Volume: 38, Issue:3 Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Da	1997
Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Drug Resistance, Neoplasm; Etoposide;	1997
Sequential mitoxantrone, daunorubicin, and cytosine arabinoside for patients with newly diagnosed acute myelocytic leukemia. American journal of hematology, 1997, Volume: 56, Issue:4 Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti	1997
Autologous peripheral blood progenitor cell transplantation mobilized with high-dose cytarabine in acute myeloid leukemia in first complete remission. Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:2 Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purgi	1998
Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy. Seminars in oncology, 1998, Volume: 25, Issue:4 Suppl 10 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Daunorubicin; Female;	1998
Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia. Medical oncology (Northwood, London, England), 1998, Volume: 15, Issue:3 Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daun	1998
High single dose of mitoxantrone and cytarabine in acute non-lymphocytic leukemia: a pharmacokinetic and clinical study. Therapeutic drug monitoring, 1998, Volume: 20, Issue:6 Topics: Adult; Aged; Amsacrine; Chromatography, High Pressure Liquid; Cytarabine; Drug Administration Schedu	1998
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood, 1999, Jun-15, Volume: 93, Issue:12 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabin	1999
GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly. Journal of experimental & clinical cancer research : CR, 1999, Volume: 18, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cytarabi	1999
Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS. Advances in experimental medicine and biology, 1999, Volume: 457 Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protoco	1999
Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC). Advances in experimental medicine and biology, 1999, Volume: 457 Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe	1999
A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia. Cancer, 1999, Dec-01, Volume: 86, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Cr	1999
Continuous-infusion carboplatin in combination with idarubicin or mitoxantrone for high-risk acute myeloid leukemia: a randomised phase II study. Leukemia & lymphoma, 1999, Volume: 36, Issue:1-2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Idarubicin	1999
Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:9 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclosporine; D	2000
Poor prognosis acute myelogenous leukemia: 1 - response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine). Leukemia research, 2000, Volume: 24, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cytarabi	2000
Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia. Leukemia research, 2000, Volume: 24, Issue:11 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cytarabine; Dose-Response Relationship, Drug; Drug A	2000
Treatment of childhood acute myelogenous leukemia with allogeneic and autologous stem cell transplantation during the first remission: a report from the Kyushu-Yamaguchi Children's Cancer Study group in Japan. Pediatric hematology and oncology, 2000, Volume: 17, Issue:8 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Chil	2000
Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor. American journal of clinical oncology, 2001, Volume: 24, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte-Macrophage Col	2001
Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, May-15, Volume: 19, Issue:10 Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Pre	2001
Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. Leukemia, 2001, Volume: 15, Issue:5 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transp	2001
High remission rate in acute myeloblastic leukemia with only two days of chemotherapy. Leukemia & lymphoma, 2001, Volume: 41, Issue:3-4 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Cytarabine; Cyto	2001
Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia. Onkologie, 2001, Volume: 24, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation	2001
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood, 2001, Oct-15, Volume: 98, Issue:8 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Diseas	2001
Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group. Blood, 2001, Dec-15, Volume: 98, Issue:13 Topics: Aclarubicin; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosome	2001
Outcomes in patients treated with gemtuzumab ozogamicin for relapsed acute myelogenous leukemia. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2002, May-15, Volume: 59, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Anti	2002
Outcomes in patients treated with gemtuzumab ozogamicin for relapsed acute myelogenous leukemia. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2002, May-15, Volume: 59, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Anti	2002
Outcomes in patients treated with gemtuzumab ozogamicin for relapsed acute myelogenous leukemia. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2002, May-15, Volume: 59, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Anti	2002
Outcomes in patients treated with gemtuzumab ozogamicin for relapsed acute myelogenous leukemia. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2002, May-15, Volume: 59, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Anti	2002
Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-15, Volume: 20, Issue:12 Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation	2002
Treatment of acute nonlymphocytic leukemia by combination of recombinant human granulocyte colony-stimulating factor and cytotoxic agents: a report of six cases. International journal of hematology, 1992, Volume: 55, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cytarabine; Daunorubicin; Drug Ev	1992
[The first Russian trial of treating patients with acute nonlymphoblastic leukemias with novantrone combined with cytosar]. Terapevticheskii arkhiv, 1992, Volume: 64, Issue:7 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Tolerance; Femal	1992
Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood, 1992, Dec-15, Volume: 80, Issue:12 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Disorders;	1992
Mitoxantrone and high dose Ara-C for the treatment of ANLL in childhood: a pilot study of the EORTC CLCG (EORTC 58 872). Leukemia, 1992, Volume: 6 Suppl 2 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Dru	1992
Treatment of acute non lymphoid leukemia (ANLL) in elderly patients. The GIMEMA experience. Leukemia, 1992, Volume: 6 Suppl 2 Topics: Age Factors; Aged; Aged, 80 and over; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protoco	1992
High remission rate in acute myeloblastic leukemia in children treated with high-dose methylprednisolone. European journal of haematology, 1992, Volume: 48, Issue:4 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Cy	1992
Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study. Haematology and blood transfusion, 1990, Volume: 33 Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bon	1990
High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison. Seminars in hematology, 1991, Volume: 28, Issue:3 Suppl 4 Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship,	1991
[Preliminary results of the treatment of acute leukemia with mitoxantrone]. Acta haematologica Polonica, 1991, Volume: 22, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administra	1991
Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. Leukemia, 1990, Volume: 4, Issue:3 Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin;	1990
Combination of mitoxantrone and etoposide in patients aged over 60 years with untreated acute myelogenous leukemia. Haematology and blood transfusion, 1990, Volume: 33 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Etoposide; Humans; Leuke	1990
Mitoxantrone, cytosine arabinoside, and VP-16 in 36 patients with relapsed and refractory acute myeloid leukemia. Haematology and blood transfusion, 1990, Volume: 33 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide;	1990
Mitoxantrone and etoposide in patients with relapsed and refractory acute nonlymphocytic leukemia. Haematology and blood transfusion, 1990, Volume: 33 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Etoposide; Humans; Leukemia,	1990
Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial. Haematology and blood transfusion, 1990, Volume: 33 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cytarabine; Dau	1990
Proposal for the classification of relapsed and refractory acute myeloid leukemias as the basis for an age-adjusted randomized comparison of sequentially applied high-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone (S-H Haematology and blood transfusion, 1990, Volume: 33 Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Child	1990
Mitoxantrone for refractory and relapsed acute leukemia. Cancer, 1990, Aug-01, Volume: 66, Issue:3 Topics: Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Multicen	1990
Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia. American journal of hematology, 1990, Volume: 35, Issue:1 Topics: Adult; Aged; Clinical Trials as Topic; Cytarabine; Delayed-Action Preparations; Female; Humans; Leuk	1990
High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: a prospective randomized study. European journal of haematology, 1990, Volume: 45, Issue:3 Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans;	1990
Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia. American journal of clinical oncology, 1990, Volume: 13, Issue:6 Topics: Adult; Aged; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Leukem	1990
High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia--preliminary clinical and pharmacological data of a randomized comparison. Cancer treatment reviews, 1990, Volume: 17, Issue:2-3 Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; H	1990
Age related randomized comparison of sequentially applied high-dose versus intermediate dose cytosine arabinoside in combination with mitoxantrone (S-HAM) in the treatment of relapsed and refractory acute myeloid leukemia: study design and preliminary res Onkologie, 1989, Volume: 12, Issue:1 Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarab	1989
High-dose cytosine arabinoside and mitoxantrone: preliminary results of a pilot study with sequential application (S-HAM) indicating a high antileukemic activity in refractory acute leukemias. Onkologie, 1988, Volume: 11, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; C	1988
[Alternatives and further development of therapy of acute myeloid leukemia in adults. Update of West German multicenter studies]. Onkologie, 1987, Volume: 10, Issue:1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combine	1987
[High dosage ARA-C in combination with mitoxantrone in therapy of acute myeloid leukemia in childhood. Initial results of the AML BFM-85 recurrence study]. Onkologie, 1987, Volume: 10, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Cytarabine; Dose-Re	1987
Mitoxantrone and VP-16 in refractory acute myelogenous leukemia. Haematology and blood transfusion, 1987, Volume: 30 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administration Schedu	1987
Phase I/II trial of high-dose cytosine arabinoside and mitoxantrone in adult refractory acute myeloid leukemia. Haematology and blood transfusion, 1987, Volume: 30 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Drug Administr	1987
Postinduction and preremission chemotherapy alternatives for adult AML: three multicenter studies of the AML Cooperative Group. Haematology and blood transfusion, 1987, Volume: 30 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin;	1987

mitoxantrone and Acute Myelogenous Leukemia

Research Excerpts

Research

Studies (425)

Authors

Clinical Trials (34)

Trial Overview

Trial Outcomes

Number of Participants Experiencing Dose Limiting Toxicities (DLTs) at the Maximum Tolerated Dose (MTD) for Decitabine When Given Together With G-CLAM Toxicities (DLTs) (Phase I)

Number of Participants Who Achieved Remission (Complete Remission [CR]/CR With Incomplete Peripheral Blood Count Recovery [CRi])

Number of Participants With Event-free Survival

Number of Participants With Minimal Residual Disease Negative (MRDneg) Complete Remission (Phase II)

Number of Participants With Overall Survival

Number of Participants With Relapse-free Survival

Complete Response Rate

Disease-free Survival

Incidence of Toxicities, Characterized by Number of Events by Treatment and Grade

Number of Patients With Minimal Residual Disease

Overall Survival

Progression-free Survival

Overall Survival

Phase I Only: Optimal Dose of AMD3100 Plus MEC in Patients With Relapsed or Refractory AML

Relapse-free Survival

Time to Neutrophil Recovery

Time to Platelet Recovery

Characterize the Mobilization of Leukemic Cells With AMD3100 by Measuring the Peak Mobilization of AML Blasts (Phase I)

Characterize the Mobilization of Leukemic Cells With AMD3100 by Measuring the Peak Mobilization of Total Leukocytes (Phase I)

Phase II Only: Complete Response Rate of AMD3100 + MEC

Safety and Tolerability of AMD3100 + MEC.

Treatment Failure

Complete Response

Disease Free Survival

Overall Survival

Compare Qualitative and Quantitative Toxicities of These Regimens in These Patients

Response Rate of the Combination of Bortezomib and Melphalan in Patients With AML and High-risk MDS.

Reviews

Trials

Other Studies

Article	Year
Effect of Dose Ratio on Mitoxantrone and Daunorubicin in Acute Myeloid Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clinical lymphoma, myeloma & leukemia, 2021, Volume: 21, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Female; Humans; Leukemia, Myelo	2021
Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state. American journal of hematology, 2017, Volume: 92, Issue:9 Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cladribine; Co	2017
Myeloid disorders after autoimmune disease. Best practice & research. Clinical haematology, 2019, Volume: 32, Issue:1 Topics: Arthritis, Rheumatoid; Cyclophosphamide; Genetic Predisposition to Disease; Humans; Immunosuppressiv	2019
Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. Journal of neuroimmunology, 2019, 07-15, Volume: 332 Topics: Cardiomyopathies; Disease Progression; Epidemiologic Studies; Humans; Immunosuppressive Agents; Infe	2019
The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia. The Cochrane database of systematic reviews, 2015, Jun-03, Issue:6 Topics: Anthracyclines; Antibiotics, Antineoplastic; Daunorubicin; Doxorubicin; Humans; Idarubicin; Inductio	2015
Idiopathic hyperammonemia (IHA) after dose-dense induction chemotherapy for acute myeloid leukemia: Case report and review of the literature. Leukemia research, 2009, Volume: 33, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cytarabine; Fema	2009
[Bacillus cereus sepsis and subarachnoid hemorrhage following consolidation chemotherapy for acute myelogenous leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bacillaceae Infections; Bacillus cereus; Cytarabine;	2009
Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature. Puerto Rico health sciences journal, 2009, Volume: 28, Issue:2 Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chromosome	2009
New induction and postinduction strategies in acute myeloid leukemia. Current opinion in hematology, 2012, Volume: 19, Issue:2 Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols;	2012
[Current treatment of acute myeloid leukaemia in adults]. Orvosi hetilap, 2012, Feb-19, Volume: 153, Issue:7 Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast	2012
[A systematic review of MA versus IA regimen for patients with acute myelogenous leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:12 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin;	2011
Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood, 2003, Jul-15, Volume: 102, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromoso	2003
Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients. Multiple sclerosis (Houndmills, Basingstoke, England), 2004, Volume: 10, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosome Inversion; C	2004
A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia. Hematological oncology, 2004, Volume: 22, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Su	2004
Severe toxicity following induction chemotherapy for acute myelogenous leukemia in a patient with Werner's syndrome. Leukemia & lymphoma, 2005, Volume: 46, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA Helicases; Etoposide; Exodeox	2005
Multidrug resistance and stem cells in acute myeloid leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jun-01, Volume: 12, Issue:11 Pt 1 Topics: ADP-ribosyl Cyclase 1; Antigens, CD34; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Ca	2006
Treatment of relapsed acute myeloid leukaemia. Reviews on recent clinical trials, 2006, Volume: 1, Issue:2 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colon	2006
Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases. Blood, 1995, Nov-01, Volume: 86, Issue:9 Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Phytogenic; Antineoplastic Combine	1995
Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia. Drugs & aging, 1996, Volume: 9, Issue:2 Topics: Adult; Antineoplastic Agents; Humans; Leukemia, Myeloid, Acute; Mitoxantrone	1996
[Chemotherapy of relapsed AML and ALL]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 1996, Volume: 37, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Etoposide; Granulocyte Col	1996
Mitoxantrone in the treatment of acute myelogenous leukemia: a review. Hematology and cell therapy, 1997, Volume: 39, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Genes,	1997
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia. Bone marrow transplantation, 2001, Volume: 28, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation	2001
New drugs in acute myelogenous leukemia: a review. Journal of clinical pharmacology, 1992, Volume: 32, Issue:4 Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as	1992
Pharmacologically directed design of leukemia therapy. Haematology and blood transfusion, 1990, Volume: 33 Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleo	1990
Eccrine squamous syringometaplasia. A cutaneous sweat gland reaction in the histologic spectrum of 'chemotherapy-associated eccrine hidradenitis' and 'neutrophilic eccrine hidradenitis'. Archives of dermatology, 1990, Volume: 126, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Cytarabine; Eccrine Glands; Humans;	1990
Treatment of relapsed and refractory acute myeloid leukemia in adults. Bone marrow transplantation, 1989, Volume: 4 Suppl 1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance; Etoposide; Human	1989
Etoposide: fifteen years experience. Bone marrow transplantation, 1989, Volume: 4 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Hodgkin Dise	1989
Mitoxantrone and amsacrine: two important agents for the treatment of acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL). Bone marrow transplantation, 1989, Volume: 4 Suppl 1 Topics: Amsacrine; Daunorubicin; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Precursor	1989
Mitoxantrone in the treatment of refractory and relapsed non-lymphoblastic acute leukaemia. Bone marrow transplantation, 1989, Volume: 4 Suppl 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mitoxa	1989

Intervention	Participants (Number)
	Abdominal pain/cramping	Abscess	Alkaline phosphatase increase	Allergic reaction	Allergic rhinitis	Alopecia	Anal incontinence	Anemia	Anorexia	Anxiety/agitation	Apnea	Arrhythmia, NOS	Arthralgia	Arthritis	Ataxia (incoordination)	Bilirubin increase	Blurred vision	Bone pain	Bruising	CPK increase	Cardiac ischemia/infarction	Cardiovascular-other	Cataract	Cerebrovascular ischemia	Chest pain,not cardio or pleur	Conduction abnormality/block	Confusion	Conjunctivitis	Constipation/bowel obstruction	Cough	Creatinine increase	Cushingoid appearance	Dehydration	Depression	Diarrhea without colostomy	Dizziness/light headedness	Dry eye	Dry skin	Dysmenorrhea	Dyspepsia/heartburn	Dyspnea	Dysuria	Ear-other	Edema	Endocrine-other	Epistaxis	Erectile impotence	Eryth/rash/eruption/desq, NOS	Esophagitis/dysphagia	Eye-other	Fatigue/malaise/lethargy	Febrile neutropenia	Feminization of male	Fever without neutropenia	Fever, NOS	Flatulence	Flu-like symptoms-other	Flushing	GGT increase	GI Mucositis, NOS	GI-other	GU-other	Gastritis	Gastritis/ulcer, NOS	Glaucoma	Gynecomastia	Headache	Hematologic-other	Hematuria	Hemolysis	Hemoptysis	Hemorrhage-other	Hiccoughs	Hot flashes	Hypercalcemia	Hypercholesterolemia	Hyperglycemia	Hyperkalemia	Hypermagnesemia	Hypernatremia	Hypertension	Hypertriglyceridemia	Hypoalbuminemia	Hypocalcemia	Hypoglycemia	Hypokalemia	Hypomagnesemia	Hyponatremia	Hypotension	Hypothyroidism	Hypoxia	Incontinence	Infection w/o 3-4 neutropenia	Infection with 3-4 neutropenia	Infection, unk ANC	Inner ear-hearing loss	Insomnia	Invol. movement/restlessness	Joint,muscle,bone-other	LVEF decrease/CHF	Leukopenia	Libido loss	Local injection site reaction	Lung-other	Lymphopenia	Male infertility	Melena/ GI bleeding	Memory loss	Metabolic-other	Middle ear-hearing loss/otitis	Mood/consciousness change, NOS	Mouth dryness	Muscle weakness (not neuro)	Myalgia	Myalgia/arthralgia, NOS	Myocarditis	Nail changes	Nausea	Neuro-other	Neuropathic pain	Neutropenia/granulocytopenia	PRBC transfusion	Pain-other	Palpitations	Pelvic pain	Pericar. effusion/pericarditis	Personality/behavioral change	Phlebitis	Pigmentation changes/yellowing	Pleural effusions	Pneumonitis/infiltrates	Proctitis	Proteinuria	Pruritus	RT-GI mucositis, NOS	RT-focal dermatitis, NOS	RT-late bladder morbidity	RT-late intestinal morbidity	RT-pain	Rash/desquamation	Rectal bleeding/hematochezia	Rectal/perirectal pain	Respiratory infect w/o neutrop	Respiratory infection, unk ANC	Rigors/chills	SGOT (AST) increase	SGPT (ALT) increase	Salivary change, NOS	Second primary	Seizures	Sensory neuropathy	Sexual/reproductive-other	Sinus bradycardia	Skin-other	Speech impairment	Stomatitis/pharyngitis	Supraventricular arrhythmia	Surgery-wound infection	Sweating	Syncope	Taste disturbance	Tearing	Thrombocytopenia	Thrombosis/embolism	Tremor	Troponin T (cTnT) increase	Urinary frequency/urgency	Urinary retention	Urinary tr infect w/ neutrop	Urinary tr infect w/o neutrop	Urinary tr infection, unk ANC	Urine color change	Urticaria	Ventricular arrhythmia	Vertigo	Vision,NOS	Voice change/stridor/larynx	Vomiting	Weakness (motor neuropathy)	Weight gain	Weight loss
Arm I: Bicalutamide + Goserelin	19	0	11	1	2	91	2	52	7	52	1	0	43	17	1	5	3	19	1	0	1	0	5	1	11	1	6	0	57	10	7	0	0	80	55	33	1	11	0	7	21	14	0	40	3	0	181	0	2	1	258	0	1	0	1	2	2	5	1	0	12	9	2	0	2	140	37	1	9	0	0	1	0	439	4	5	44	0	0	0	38	2	1	1	0	8	1	3	3	2	0	88	5	0	1	3	79	2	11	0	14	163	11	0	4	2	0	15	0	0	2	10	55	26	1	0	4	26	5	0	11	0	112	1	9	0	12	0	0	0	0	4	3	13	0	3	1	2	1	46	12	7	1	1	7	42	22	0	0	1	37	2	0	11	0	5	0	0	138	0	1	0	3	2	0	0	86	13	0	1	3	3	3	1	1	0	0	10	3	179	12
Arm II: Mitoxantrone + Prednisone + Bivalutamid + Goserelin	41	1	11	5	16	131	2	141	41	62	1	1	64	17	1	20	6	34	14	2	1	5	6	0	19	0	14	4	117	34	17	8	6	85	75	71	5	28	1	44	49	11	2	56	2	2	146	2	13	6	357	2	0	9	6	3	6	4	0	10	20	9	0	1	0	100	82	1	13	1	1	4	4	422	5	2	78	4	1	4	38	0	6	7	1	11	1	2	11	0	4	71	10	2	4	2	92	2	27	8	317	133	17	2	49	3	2	12	1	1	3	13	77	45	12	1	57	205	4	1	239	3	127	6	11	1	11	5	3	1	1	4	1	23	1	1	0	1	0	63	10	5	7	8	24	42	26	1	6	1	57	1	4	11	1	49	2	1	129	3	46	6	35	5	2	1	101	7	1	2	2	44	4	0	1	1	6	51	6	151	29